


**CUMULATIVE
SUPPLEMENT 3
MARCH 2021**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2021

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41th EDITION

**Cumulative Supplement 3
March 2021**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT	vi
1.3	APPLICANT NAME CHANGES	vii
1.4	LEVOTHYROXINE SODIUM	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Product Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

**CUMULATIVE SUPPLEMENT 3
MARCH 2021**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

AKORN INC
(AKORN)

AKORN INC
(AKORN INC)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AKORN OPERATING CO LLC
(AKORN)

AKORN OPERATING CO LLC
(AKORN)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS
-----	-----------------------------------	-------	-------	---------	---	----

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2020</u>	<u>MAR</u> <u>2021</u>	<u>JUN</u> <u>2021</u>	<u>SEP</u> <u>2021</u>	<u>DEC</u> <u>2021</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20478	20726			
	2659	2671			
	(13.0%)	(12.9%)			
MULTISOURCE	17819	18055			
	(87.0%)	(87.1%)			
THERAPEUTICALLY EQUIVALENT	17746	17990			
	(86.7%)	(86.8%)			

NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)	65 (0.3%)
EXCEPTIONS ⁴	54 (0.3%)	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	22	29
NUMBER OF APPLICANTS	1185	1184

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ACETAMINOPHEN

POWDER; INTRAVENOUS
 ACETAMINOPHEN

	+ @ MYLAN LABS LTD	1GM/VIAL	N206610	001	Jan 15, 2021	Jan NEWA
	SOLUTION; INTRAVENOUS					
	ACETAMINOPHEN					
	+! B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Feb NEWA
	+!	1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Feb NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	XSPIRE PHARMA	300MG; 50MG; 40MG	A206615	001	Aug 04, 2017	Feb CAHN
----	---------------	-------------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB	NOSTRUM LABS INC	325MG; 50MG; 40MG; 30MG	A075929	001	Apr 22, 2002	Jan CAHN
----	------------------	-------------------------	---------	-----	--------------	----------

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
 OXYCODONE AND ACETAMINOPHEN

AA	CHARTWELL	325MG; 5MG	A207834	001	Aug 15, 2019	Jan CAHN
AA		325MG; 7.5MG	A207834	002	Aug 15, 2019	Jan CAHN
AA		325MG; 10MG	A207834	003	Aug 15, 2019	Jan CAHN
	ROXICET					
	@ HIKMA	325MG; 5MG	A087003	001		Jan DISC

ACETAZOLAMIDE

TABLET; ORAL
 ACETAZOLAMIDE

AB	APPCO	125MG	A211372	001	Feb 22, 2021	Feb NEWA
AB		250MG	A211372	002	Feb 22, 2021	Feb NEWA

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION
 TUDORZA PRESSAIR

	+! ASTRAZENECA	0.4MG/INH	N202450	001	Jul 23, 2012	Feb CAHN
--	----------------	-----------	---------	-----	--------------	----------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION
 DUAKLIR PRESSAIR

	ASTRAZENECA	0.4MG/INH; 0.012MG/INH	N210595	001	Mar 29, 2019	Feb CAHN
--	-------------	------------------------	---------	-----	--------------	----------

ACYCLOVIR

SUSPENSION; ORAL
 ACYCLOVIR

AB	VISTAPHARM	200MG/5ML	A213951	001	Jan 11, 2021	Jan NEWA
----	------------	-----------	---------	-----	--------------	----------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
 ACYCLOVIR SODIUM

AP	ZYDUS PHARMS	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CHRS
AP	!	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CPOT

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL
 EPIDUO FORTE

	+! GALDERMA LABS	0.3%; 2.5%	N207917	001	Jul 15, 2015	Feb CTEC
--	------------------	------------	---------	-----	--------------	----------

ADENOSINE

SOLUTION; INTRAVENOUS
 ADENOSINE

AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Feb CMFD
AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Feb CMFD

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

AB	DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jan NEWA
	@ LUPIN LTD	200MG	A211636	001	Jun 10, 2020	Jan DISC
AB	MSN	200MG	A213435	001	Jan 21, 2021	Jan NEWA

ALBUTEROL SULFATE

TABLET; ORAL

ALBUTEROL SULFATE

AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Feb CMFD
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Feb CMFD

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ AUROBINDO PHARMA LTD EQ 0.083% BASE; 0.017%

A206532	001	Jul 08, 2020	Jan DISC
---------	-----	--------------	----------

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

	+ @ PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jan CAHN
AP	+	0.01MG/VIAL	N020379	001	Jul 06, 1995	Jan CAHN
AP	+!	0.02MG/VIAL	N020379	002	Jul 06, 1995	Jan CAHN
AP	+!	0.04MG/VIAL	N020379	004	May 19, 1997	Jan CAHN

CAVERJECT IMPULSE

PFIZER

0.01MG/VIAL

N021212	001	Jun 11, 2002	Jan CAHN
---------	-----	--------------	----------

0.02MG/VIAL

N021212	002	Jun 11, 2002	Jan CAHN
---------	-----	--------------	----------

PROSTIN VR PEDIATRIC

AP	+!	PFIZER	0.5MG/ML	N018484	001	Jan CAHN
----	----	--------	----------	---------	-----	----------

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

@ WOCKHARDT BIO AG 50MG/5ML

A075060	001	Dec 24, 1998	Jan DISC
---------	-----	--------------	----------

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

@ INVAGEN PHARMS 100MG

A207571	001	Jan 31, 2017	Jan DISC
---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

	+ ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
	+!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan CAHN
	+ ADAMAS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
	+!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan CAHN

AMINOCAPROIC ACID

SOLUTION; ORAL

AMICAR

AA	+!	AKORN	0.25GM/ML	N015230	002	Feb CPOT
AA	+!		1.25GM/5ML	N015230	002	Feb CDFR

AMINOCAPROIC ACID

AA	AMNEAL	0.25GM/ML	A212780	001	Aug 23, 2019	Feb CPOT
AA		1.25GM/5ML	A212780	001	Aug 23, 2019	Feb CDFR
AA	LEADING PHARMA LLC	0.25GM/ML	A214140	001	Jan 26, 2021	Feb CPOT
AA		1.25GM/5ML	A214140	001	Jan 26, 2021	Feb CDFR
AA	TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Feb CPOT
AA		1.25GM/5ML	A212494	001	Aug 11, 2020	Feb CDFR
AA	VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Feb CPOT
AA		1.25GM/5ML	A212814	001	Feb 26, 2020	Feb CDFR

SYRUP; ORAL

AMINOCAPROIC ACID

AA	LEADING PHARMA LLC	1.25GM/5ML	A214140	001	Jan 26, 2021	Jan NEWA
----	--------------------	------------	---------	-----	--------------	----------

TABLET; ORAL

AMINOCAPROIC ACID

AB	LEADING PHARMA LLC	500MG	A213928	001	Feb 12, 2021	Feb NEWA
AB		1GM	A213928	002	Feb 12, 2021	Feb NEWA

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	RUBICON	100MG	A078578	002	Feb 26, 2021	Feb	NEWA
AB		400MG	A078578	003	Feb 26, 2021	Feb	NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	MANKIND PHARMA	10MG	A213999	001	Feb 19, 2021	Feb	NEWA
AB		25MG	A213999	002	Feb 19, 2021	Feb	NEWA
AB		50MG	A213999	003	Feb 19, 2021	Feb	NEWA
AB		75MG	A213999	004	Feb 19, 2021	Feb	NEWA
AB		100MG	A213999	005	Feb 19, 2021	Feb	NEWA
AB		150MG	A213999	006	Feb 19, 2021	Feb	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

@ WOCKHARDT

@

@

EQ 2.5MG BASE

EQ 5MG BASE

EQ 10MG BASE

A078500	001	Sep 06, 2007	Jan	DISC
A078500	002	Sep 06, 2007	Jan	DISC
A078500	003	Sep 06, 2007	Jan	DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Jan	CAHN
----	---------	------------------------------------	---------	-----	--------------	-----	------

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	RHODES PHARMS	2.5MG; 2.5MG; 2.5MG; 2.5MG	A213111	003	Jan 13, 2021	Jan	NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A213111	005	Jan 13, 2021	Jan	NEWA
AB		5MG; 5MG; 5MG; 5MG	A213111	006	Jan 13, 2021	Jan	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A213111	001	Jan 13, 2021	Jan	NEWA
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A213111	002	Jan 13, 2021	Jan	NEWA
AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A213111	004	Jan 13, 2021	Jan	NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A213111	007	Jan 13, 2021	Jan	NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

AA	GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021	Jan	NEWA	
AA		10MG	A212186	002	Jan 27, 2021	Jan	NEWA	
	@ MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jan	DISC	
	@	10MG	A213898	002	Jul 14, 2020	Jan	DISC	
>D>	AA	NOVAST LABS	5MG	A213763	001	Aug 24, 2020	Mar	DISC
>A>	@		5MG	A213763	001	Aug 24, 2020	Mar	DISC
>D>	AA		10MG	A213763	002	Aug 24, 2020	Mar	DISC
>A>	@		10MG	A213763	002	Aug 24, 2020	Mar	DISC
AA	SPECGX LLC	5MG	A213583	001	Jan 22, 2021	Jan	NEWA	
AA		10MG	A213583	002	Jan 22, 2021	Jan	NEWA	
AA	SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Jan	NEWA	
AA		10MG	A214574	002	Jan 27, 2021	Jan	NEWA	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D>	@ HANFORD GC	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Mar	CAHN
>D>	AP	EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Mar	CAHN
>D>	AP	EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Mar	CAHN
>D>	@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Mar	CAHN
>D>	AP	EQ 1GM BASE/VIAL	A062772	001	Apr 15, 1993	Mar	CAHN
>D>	@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Mar	CAHN
>D>	AP	EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Mar	CAHN
>D>	@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Mar	CAHN
>D>	AP	EQ 10GM BASE/VIAL	A063142	001	Apr 15, 1993	Mar	CAHN

INJECTABLE; INJECTION
AMPICILLIN SODIUM

>A>	@ HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Mar CAHN
>A>	AP	EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Mar CAHN
>A>	AP	EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Mar CAHN
>A>	@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Mar CAHN
>A>	AP	EQ 1GM BASE/VIAL	A062772	001	Apr 15, 1993	Mar CAHN
>A>	@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Mar CAHN
>A>	AP	EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Mar CAHN
>A>	@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Mar CAHN
>A>	AP	EQ 10GM BASE/VIAL	A063142	001	Apr 15, 1993	Mar CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

>D>	AP	HANFORD GC	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065176	001	Nov 30, 2005	Mar CAHN
>D>	AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065176	002	Nov 30, 2005	Mar CAHN
>D>	AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A065188	001	Nov 25, 2005	Mar CAHN
>A>	AP	HQ SPECLT PHARMA	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065176	001	Nov 30, 2005	Mar CAHN
>A>	AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065176	002	Nov 30, 2005	Mar CAHN
>A>	AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A065188	001	Nov 25, 2005	Mar CAHN

APREMILAST

TABLET; ORAL
APREMILAST

AB	UNICHEM	10MG	A211819	001	Feb 17, 2021	Feb NFTG
AB		20MG	A211819	002	Feb 17, 2021	Feb NFTG
AB		30MG	A211819	003	Feb 17, 2021	Feb NFTG

ARGATROBAN

INJECTABLE; INJECTION
ARGATROBAN

AP	CAPLIN	50MG/50ML (1MG/ML)	A214235	001	Jan 21, 2021	Jan NFTG
----	--------	--------------------	---------	-----	--------------	----------

ARSENIC TRIOXIDE

INJECTABLE; INJECTION
ARSENIC TRIOXIDE

AP	AMNEAL	1MG/ML	A210739	001	Jan 25, 2021	Jan NEWA
	@ INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021	Feb DISC
AP		2MG/ML	A209315	002	Jan 14, 2021	Jan NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 1.7MG/VIAL; 1MG/VIAL; 1.4MG/V IAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb CAIN
---	-------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

ASENAPINE MALEATE

TABLET; SUBLINGUAL
ASENAPINE MALEATE

AB	BRECKENRIDGE	EQ 5MG BASE	A205960	003	Mar 08, 2021	Feb NEWA
----	--------------	-------------	---------	-----	--------------	----------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL
ATOMOXETINE HYDROCHLORIDE

>A>	AB	HETERO LABS LTD V	10MG	A202682	001	Mar 11, 2021	Mar NEWA
>A>	AB		18MG	A202682	002	Mar 11, 2021	Mar NEWA
>A>	AB		25MG	A202682	003	Mar 11, 2021	Mar NEWA
>A>	AB		40MG	A202682	004	Mar 11, 2021	Mar NEWA
>A>	AB		60MG	A202682	005	Mar 11, 2021	Mar NEWA
>A>	AB		80MG	A202682	006	Mar 11, 2021	Mar NEWA
>A>	AB		100MG	A202682	007	Mar 11, 2021	Mar NEWA
	AB	@ MYLAN	10MG	A079021	001	Feb 18, 2021	Feb DISC
	AB	@	18MG	A079021	001	Feb 18, 2021	Feb NEWA
	AB	@	18MG	A079021	002	Feb 18, 2021	Feb DISC
	AB	@	18MG	A079021	002	Feb 18, 2021	Feb NEWA
	AB	@	25MG	A079021	003	Feb 18, 2021	Feb DISC
	AB	@	25MG	A079021	003	Feb 18, 2021	Feb NEWA

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE							
	@	40MG	A079021	004	Feb 18, 2021	Feb	DISC
AB		40MG	A079021	004	Feb 18, 2021	Feb	NEWA
	@	60MG	A079021	005	Feb 18, 2021	Feb	DISC
AB		60MG	A079021	005	Feb 18, 2021	Feb	NEWA
	@	80MG	A079021	006	Feb 18, 2021	Feb	DISC
AB		80MG	A079021	006	Feb 18, 2021	Feb	NEWA
	@	100MG	A079021	007	Feb 18, 2021	Feb	DISC
AB		100MG	A079021	007	Feb 18, 2021	Feb	NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM							
AB	ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018	Jan	CAHN
AB		EQ 20MG BASE	A209288	002	Dec 21, 2018	Jan	CAHN
AB		EQ 40MG BASE	A209288	003	Dec 21, 2018	Jan	CAHN
AB		EQ 80MG BASE	A209288	004	Dec 21, 2018	Jan	CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

	+ @	ORGANON	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb	CAHN
	+ @		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb	CAHN
	+ @		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb	CAHN
	+ @		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb	CAHN

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

>A>	AB	BIONPHARMA INC	750MG/5ML	A212918	001	Mar 30, 2021	Mar	NEWA
-----	----	----------------	-----------	---------	-----	--------------	-----	------

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

>D>	AA	+	HOSPIRA	1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Mar	CTEC
>A>	AP	+		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Mar	CTEC
>D>	AA		INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar	CTEC
>A>	AP			1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar	CTEC

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

>A>	AP	ACCORD HLTHCARE	8MG/20ML (0.4MG/ML)	A213424	001	Mar 19, 2021	Mar	NFTG
-----	----	-----------------	---------------------	---------	-----	--------------	-----	------

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	WINDER LABS LLC	0.025MG;2.5MG	A211362	001	Jan 27, 2021	Jan	NEWA
----	-----------------	---------------	---------	-----	--------------	-----	------

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

	+ @	MYLAN	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jan	CAHN
--	-----	-------	-------------------	---------	-----	--------------	-----	------

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;INTRAVENOUS

AVYCAZ

	+	ALLERGAN	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Jan	CDFR
--	---	----------	------------------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	PERRIGO UK FINCO	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A208111	001	Feb 18, 2021	Feb	NEWA
----	------------------	------------------------------------	---------	-----	--------------	-----	------

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Feb	CMFD
----	------	-------------------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

AZITHROMYCIN

	@	MYLAN ASI	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Feb	DISC
--	---	-----------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL

AZITHROMYCIN

>A>	AB	YUNG SHIN PHARM	EQ 500MG BASE	A211318	001	Mar 17, 2021	Mar NEWA
	AB		EQ 600MG BASE	A211068	001	May 08, 2020	Feb CMFD

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

	AP	MAIA PHARMS INC	0.05MG/ML	A210777	001	Jan 15, 2021	Jan NEWA
		GABLOFEN					
>D>	AP	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Mar CHRS
>A>	AP	+	0.05MG/ML	N022462	001	Nov 19, 2010	Mar CHRS
>D>	AP		0.5MG/ML	N022462	002	Nov 19, 2010	Mar CHRS
>A>	AP	+	0.5MG/ML	N022462	002	Nov 19, 2010	Mar CHRS
>D>	AP		2MG/ML	N022462	003	Nov 19, 2010	Mar CHRS
>A>	AP	+	2MG/ML	N022462	003	Nov 19, 2010	Mar CHRS

TABLET;ORAL

BACLOFEN

	AB	KARTHA	5MG	A214374	001	Mar 05, 2021	Feb NEWA
	AB		10MG	A214374	002	Mar 05, 2021	Feb NEWA
	AB		20MG	A214374	003	Mar 05, 2021	Feb NEWA

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

>A>	+	GENENTECH INC	80MG	N210854	003	Mar 18, 2021	Mar NEWA
-----	---	---------------	------	---------	-----	--------------	----------

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

LOTENSIN

	AB	+	VALIDUS PHARMS	5MG	N019851	001	Jun 25, 1991	Feb CAHN
	AB	+		10MG	N019851	002	Jun 25, 1991	Feb CAHN
	AB	+		20MG	N019851	003	Jun 25, 1991	Feb CAHN
	AB	+		40MG	N019851	004	Jun 25, 1991	Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

LOTENSIN HCT

		+	@ VALIDUS PHARMS	5MG;6.25MG	N020033	001	May 19, 1992	Feb CAHN
	AB	+		10MG;12.5MG	N020033	002	May 19, 1992	Feb CAHN
	AB	+		20MG;12.5MG	N020033	004	May 19, 1992	Feb CAHN
	AB	+		20MG;25MG	N020033	003	May 19, 1992	Feb CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

	AB	!	PERRIGO ISRAEL	5%;1.2%	A090979	001	Jun 26, 2012	Jan CHRS
			DUAC					
	AB	+	STIEFEL	5%;1.2%	N050741	001	Aug 26, 2002	Jan CHRS

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL

SERNIVO

>D>	+	ENCORE DERMAT	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Mar CAHN
>A>	+	PRIMUS PHARMS	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Mar CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

	AB	!	TARO	EQ 0.05% BASE;1%	A076493	001	Jul 28, 2004	Feb CHRS
			LOTRISONE					
		+	@ MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb DISC

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

@ WOCKHARDT

@

			5MG	A040532	001	Sep 29, 2003	Jan DISC
			50MG	A040518	001	Sep 29, 2003	Jan DISC

BEXAROTENE

	CAPSULE;ORAL						
	BEXAROTENE						
AB	TEVA PHARMS USA	75MG	A209931	001	Jan 14, 2021	Jan	NEWA

BIMATOPROST

	SOLUTION/DROPS;OPHTHALMIC						
	BIMATOPROST						
	@ AKORN	0.03%	A203299	001	Nov 08, 2018	Feb	CAHN
AT	! ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019	Jan	CHRS
AT	LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Jan	CHRS

BOSENTAN

	TABLET;ORAL						
	TRACLEER						
AB	+ ACTELION	62.5MG	N021290	001	Nov 20, 2001	Feb	CAHN
AB	+!	125MG	N021290	002	Nov 20, 2001	Feb	CAHN
	TABLET, FOR SUSPENSION;ORAL						
	TRACLEER						
	+! ACTELION	32MG	N209279	001	Sep 05, 2017	Feb	CAHN

BROMOCRIPTINE MESYLATE

	CAPSULE;ORAL						
	PARLODEL						
AB	+ VALIDUS PHARMS	EQ 5MG BASE	N017962	002	Mar 01, 1982	Feb	CAHN
	TABLET;ORAL						
	PARLODEL						
AB	+ VALIDUS PHARMS	EQ 2.5MG BASE	N017962	001		Feb	CAHN

BUDESONIDE

	CAPSULE;ORAL						
	BUDESONIDE						
	@ BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Jan	DISC

>D> BUPIVACAINE

>D>	SOLUTION, EXTENDED RELEASE;INFILTRATION						
>D>	POSIMIR						
>D>	+! DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Mar	DISC
>A>	+ @	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Mar	DISC
	+!	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Feb	NEWA

BUPIVACAINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	BUPIVACAINE HYDROCHLORIDE						
AP	HIKMA PHARMS	0.25%	A205141	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A205141	002	Feb 11, 2021	Feb	NEWA
	BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE						
AP	HIKMA PHARMS	0.25%	A204842	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A204842	002	Feb 11, 2021	Feb	NEWA
AP		0.75%	A204842	003	Feb 11, 2021	Feb	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

	TABLET;SUBLINGUAL						
	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE						
	@ MAYNE PHARMA INC	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Jan	DISC
	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jan	DISC

BUPROPION HYDROBROMIDE

	TABLET, EXTENDED RELEASE;ORAL						
	APLENZIN						
	+ BAUSCH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
	+	348MG	N022108	002	Apr 23, 2008	Feb	CAHN
	+!	522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL						
	BUPROPION HYDROCHLORIDE						
	@ TORRENT	100MG	A203969	001	Oct 31, 2014	Jan	DISC
	@	150MG	A203969	002	Oct 31, 2014	Jan	DISC
	@	200MG	A203969	003	Oct 31, 2014	Jan	DISC

TABLET, EXTENDED RELEASE;ORAL
WELLBUTRIN XL

AB3	+	BAUSCH	150MG	N021515	001	Aug 28, 2003	Feb CAHN
AB3	+	!	300MG	N021515	002	Aug 28, 2003	Feb CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB		RUBICON	5MG	A 075521	001	Apr 05, 2002	Feb CMFD
>A>	AB		7.5MG	A 075521	004	Mar 16, 2021	Mar NEWA
AB			10MG	A 075521	002	Apr 05, 2002	Feb CMFD
AB			15MG	A 075521	003	Apr 05, 2002	Feb CMFD
>A>	AB		30MG	A 075521	005	Mar 16, 2021	Mar NEWA

BUSULFAN

INJECTABLE; INJECTION
BUSULFAN

AP		AM REGENT	6MG/ML	A 202259	001	Dec 22, 2015	Feb CAHN
----	--	-----------	--------	----------	-----	--------------	----------

CABERGOLINE

TABLET;ORAL
DOSTINEX

	+	@ PFIZER	0.5MG	N 020664	001	Dec 23, 1996	Jan CAHN
--	---	----------	-------	----------	-----	--------------	----------

CABOTEGRAVIR SODIUM

TABLET;ORAL
VOCABRIA

	+	! VIIV HLTHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021	Jan NEWA
--	---	-----------------	--------------	---------	-----	--------------	----------

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
CABENUVA KIT

	+	! VIIV HLTHCARE	400MG/2ML (200MG/ML); 600MG/2ML (300MG/ML)	N 212888	001	Jan 21, 2021	Jan NEWA
	+	!	600MG/3ML (200MG/ML); 900MG/3ML (300MG/ML)	N 212888	002	Jan 21, 2021	Jan NEWA

CARBOPLATIN

INJECTABLE; INTRAVENOUS
CARBOPLATIN

>D>	AP		HOSPIRA	50MG/5ML (10MG/ML)	A 076517	001	Oct 14, 2004	Mar CHRS
>A>	AP	!		50MG/5ML (10MG/ML)	A 076517	001	Oct 14, 2004	Mar CHRS
>D>	AP			150MG/15ML (10MG/ML)	A 076517	002	Oct 14, 2004	Mar CHRS
>A>	AP	!		150MG/15ML (10MG/ML)	A 076517	002	Oct 14, 2004	Mar CHRS
>D>	AP			450MG/45ML (10MG/ML)	A 076517	003	Oct 14, 2004	Mar CHRS
>A>	AP	!		450MG/45ML (10MG/ML)	A 076517	003	Oct 14, 2004	Mar CHRS
>D>	AP			600MG/60ML (10MG/ML)	A 077059	001	Nov 23, 2004	Mar CHRS
>A>	AP	!		600MG/60ML (10MG/ML)	A 077059	001	Nov 23, 2004	Mar CHRS
>D>	AP	!	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A 077269	001	Oct 14, 2004	Mar CHRS
>A>	AP			50MG/5ML (10MG/ML)	A 077269	001	Oct 14, 2004	Mar CHRS
>D>	AP	!		150MG/15ML (10MG/ML)	A 077269	002	Oct 14, 2004	Mar CHRS
>A>	AP			150MG/15ML (10MG/ML)	A 077269	002	Oct 14, 2004	Mar CHRS
>D>	AP	!		450MG/45ML (10MG/ML)	A 077269	003	Oct 14, 2004	Mar CHRS
>A>	AP			450MG/45ML (10MG/ML)	A 077269	003	Oct 14, 2004	Mar CHRS
>D>	AP	!		600MG/60ML (10MG/ML)	A 077269	004	Dec 28, 2007	Mar CHRS
>A>	AP			600MG/60ML (10MG/ML)	A 077269	004	Dec 28, 2007	Mar CHRS

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION
CARBOPROST TROMETHAMINE

>A>	AP		SUNNY PHARMTECH INC	EQ 0.25MG BASE/ML	A 213118	001	Mar 25, 2021	Mar NEWA
-----	----	--	---------------------	-------------------	----------	-----	--------------	----------

CARMUSTINE

INJECTABLE; INJECTION
CARMUSTINE

>A>	AP		JIANGSU HENGRUI MED	100MG/VIAL	A 211202	001	Mar 12, 2021	Mar NEWA
-----	----	--	---------------------	------------	----------	-----	--------------	----------

CASIMERSENSOLUTION; INTRAVENOUS
AMONDYS 45

+! SAREPTA THERAPS INC 100MG/2ML (50MG/ML) N213026 001 Feb 25, 2021 Feb NEWA

CEFAZOLIN SODIUMSOLUTION; INTRAVENOUS
CEFAZOLIN IN PLASTIC CONTAINER

>A> +! BAXTER HLTHCARE CORP EQ 1GM BASE/50ML (EQ 20MG BASE/ML) N207131 002 Feb 01, 2021 Mar NEWA
 >D> EQ 2GM BASE/100ML (EQ 20MG N207131 001 Aug 07, 2015 Mar CRLD
 BASE/ML)
 >A> +! EQ 2GM BASE/100ML (EQ 20MG N207131 001 Aug 07, 2015 Mar CRLD
 BASE/ML)

CEFDINIRCAPSULE; ORAL
CEFDINIR

AB ALKEM LABS LTD 300MG A210220 001 Feb 19, 2021 Feb NEWA
 FOR SUSPENSION; ORAL
 CEFDINIR
 AB ALKEM LABS LTD 125MG/5ML A210534 001 Feb 19, 2021 Feb NEWA
 AB 250MG/5ML A210534 002 Feb 19, 2021 Feb NEWA

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

>D> AP ASTRAL EQ 1GM BASE/VIAL A212721 001 Jul 21, 2020 Mar DISC
 >A> @ EQ 1GM BASE/VIAL A212721 001 Jul 21, 2020 Mar DISC
 >D> AP EQ 2GM BASE/VIAL A212721 002 Jul 21, 2020 Mar DISC
 >A> @ EQ 2GM BASE/VIAL A212721 002 Jul 21, 2020 Mar DISC

CEFIXIMEFOR SUSPENSION; ORAL
CEFIXIME

AB ALKEM LABS LTD 100MG/5ML A211775 001 Feb 19, 2021 Feb NEWA
 AB 200MG/5ML A211775 002 Feb 19, 2021 Feb NEWA

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CLAFORAN

+ @ VALIDUS PHARMS EQ 500MG BASE/VIAL N050547 001 Feb CAHN
 + @ EQ 1GM BASE/VIAL N050547 002 Feb CAHN
 + @ EQ 2GM BASE/VIAL N050547 003 Feb CAHN
 + @ EQ 10GM BASE/VIAL N050547 004 Dec 29, 1983 Feb CAHN
 CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
 @ VALIDUS PHARMS EQ 20MG BASE/ML N050596 002 May 20, 1985 Feb CAHN
 @ EQ 40MG BASE/ML N050596 004 May 20, 1985 Feb CAHN
 CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 @ VALIDUS PHARMS EQ 20MG BASE/ML N050596 001 May 20, 1985 Feb CAHN
 @ EQ 40MG BASE/ML N050596 003 May 20, 1985 Feb CAHN

CEFTAZIDIME SODIUMINJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

@ TELIGENT EQ 10MG BASE/ML N050634 001 Apr 28, 1989 Feb CAHN
 + @ EQ 20MG BASE/ML N050634 002 Apr 28, 1989 Feb CAHN
 + @ EQ 40MG BASE/ML N050634 003 Apr 28, 1989 Feb CAHN

CEFUROXIME SODIUMINJECTABLE; INJECTION
ZINACEF

AP +! TELIGENT EQ 1.5GM BASE/VIAL N050558 003 Oct 19, 1983 Feb CAHN
 AP +! EQ 7.5GM BASE/VIAL N050558 004 Oct 23, 1986 Feb CAHN
 INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
 ZINACEF
 AB +! TELIGENT EQ 750MG BASE/VIAL N050558 002 Oct 19, 1983 Feb CAHN

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB	UNICHEM	50MG	A213301	001	Jan 12, 2021	Jan	NEWA
AB		100MG	A213301	002	Jan 12, 2021	Jan	NEWA
AB		200MG	A213301	003	Jan 12, 2021	Jan	NEWA
AB		400MG	A213301	004	Jan 12, 2021	Jan	NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

>D>	AB	YUNG SHIN PHARM	EQ 250MG BASE	A065152	001	Feb 24, 2005	Mar	DISC
>A>		@	EQ 250MG BASE	A065152	001	Feb 24, 2005	Mar	DISC
>D>	AB		EQ 500MG BASE	A065152	002	Feb 24, 2005	Mar	DISC
>A>		@	EQ 500MG BASE	A065152	002	Feb 24, 2005	Mar	DISC

CHLORHEXIDINE GLUCONATESOLUTION;DENTAL
CHLORHEXIDINE GLUCONATE

AT	BAJAJ	0.12%	A075561	001	Nov 14, 2000	Feb	CMFD
----	-------	-------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDETABLET;ORAL
CHLORPROMAZINE HYDROCHLORIDE

>A>	AB	GLENMARK PHARMS LTD	10MG	A212144	001	Mar 23, 2021	Mar	NEWA
>A>	AB		25MG	A212144	002	Mar 23, 2021	Mar	NEWA
>A>	AB		50MG	A212144	003	Mar 23, 2021	Mar	NEWA
>A>	AB		100MG	A212144	004	Mar 23, 2021	Mar	NEWA
>A>	AB		200MG	A212144	005	Mar 23, 2021	Mar	NEWA
	AB	LANNETT CO INC	10MG	A212996	001	Jan 22, 2021	Jan	NEWA
	AB		25MG	A212996	002	Jan 22, 2021	Jan	NEWA
	AB		50MG	A212996	003	Jan 22, 2021	Jan	NEWA
	AB		100MG	A212996	004	Jan 22, 2021	Jan	NEWA
	AB		200MG	A212996	005	Jan 22, 2021	Jan	NEWA
>D>	AB	MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Mar	DISC
>A>		@	10MG	A213590	001	Aug 31, 2020	Mar	DISC
>D>	AB		25MG	A213590	002	Aug 31, 2020	Mar	DISC
>A>		@	25MG	A213590	002	Aug 31, 2020	Mar	DISC
>D>	AB		50MG	A213590	003	Aug 31, 2020	Mar	DISC
>A>		@	50MG	A213590	003	Aug 31, 2020	Mar	DISC
>D>	AB		100MG	A213590	004	Aug 31, 2020	Mar	DISC
>A>		@	100MG	A213590	004	Aug 31, 2020	Mar	DISC
>D>	AB		200MG	A213590	005	Aug 31, 2020	Mar	DISC
>A>		@	200MG	A213590	005	Aug 31, 2020	Mar	DISC

CHLORPROPAMIDETABLET;ORAL
CHLORPROPAMIDE

	@	RISING	100MG	A088725	001	Aug 31, 1984	Jan	CAHN
	@		250MG	A088726	001	Aug 31, 1984	Jan	CAHN

CHOLESTYRAMINEPOWDER;ORAL
CHOLESTYRAMINE

AB	TAGI	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Feb	NEWA
AB		EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Feb	NEWA

CILOSTAZOLTABLET;ORAL
CILOSTAZOL

	@	EPIC PHARMA LLC	50MG	A077022	002	Mar 11, 2005	Jan	CMS1
>D>	AB	NOSTRUM LABS INC	50MG	A077708	001	Sep 28, 2009	Mar	DISC
>A>		@	50MG	A077708	001	Sep 28, 2009	Mar	DISC
	AB		50MG	A077708	001	Sep 28, 2009	Jan	CAHN
>D>	AB		100MG	A077708	002	Sep 28, 2009	Mar	DISC
>A>		@	100MG	A077708	002	Sep 28, 2009	Mar	DISC
	AB		100MG	A077708	002	Sep 28, 2009	Jan	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@	NOVITIUM PHARMA	300MG	A074340	001	Jun 23, 1995	Feb	CAHN
@		400MG	A074340	002	Jun 23, 1995	Feb	CAHN
@		800MG	A074339	001	Jun 23, 1995	Feb	CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

@	ZYDUS PHARMS	EQ 2MG BASE/ML	A213527	001	Aug 31, 2020	Feb	DISC
---	--------------	----------------	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

@	WOCKHARDT	250MG	A065266	001	May 31, 2006	Jan	DISC
@		500MG	A065266	002	May 31, 2006	Jan	DISC

CLASCOTERONE

CREAM; TOPICAL

WINLEVI

>D>	+	!	CASSIOPEA SPA	1%	N213433	001	Aug 26, 2020	Mar	DISC
>A>	+	@		1%	N213433	001	Aug 26, 2020	Mar	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

AB	+		PFIZER	EQ 75MG BASE	N050162	001		Feb	CAHN
AB	+			EQ 150MG BASE	N050162	002		Feb	CAHN
AB	+	!		EQ 300MG BASE	N050162	003	Apr 14, 1988	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

AA	!		PFIZER	EQ 75MG BASE/5ML	A062644	001	Apr 07, 1986	Feb	CAHN
----	---	--	--------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

AB	+	!	@	PFIZER	EQ 2% BASE	N050680	001	Aug 11, 1992	Feb	CAHN
					EQ 2% BASE	N050680	002	Mar 02, 1998	Feb	CAHN

GEL; TOPICAL

CLEOCIN T

AB	+	!		PFIZER	EQ 1% BASE	N050615	001	Jan 07, 1987	Feb	CAHN
----	---	---	--	--------	------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

>A>	AB			ENCUBE	EQ 1% BASE	A212438	001	Mar 11, 2021	Mar	NEWA
	AB			GLENMARK PHARMS LTD	EQ 1% BASE	A214251	001	Feb 10, 2021	Jan	NEWA
	AB			PERRIGO UK FINCO	EQ 1% BASE	A212104	001	Dec 31, 2020	Jan	CAHN

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

AP				PFIZER	EQ 150MG BASE/ML	A062803	001	Oct 16, 1987	Feb	CAHN
AP	+	!			EQ 150MG BASE/ML	N050441	001		Feb	CAHN

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+	@		PFIZER	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	Feb	CAHN
	+	@			EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	Feb	CAHN
	+	@			EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	Feb	CAHN

CLINDAMYCIN PHOSPHATE

@ MYLAN LABS LTD

A204748	001	Oct 10, 2017	Jan	DISC
---------	-----	--------------	-----	------

LOTION; TOPICAL

CLEOCIN T

AB	+	!		PFIZER	EQ 1% BASE	N050600	001	May 31, 1989	Feb	CAHN
----	---	---	--	--------	------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

>D>	AB			GAGE DEVELOPMENT	EQ 1% BASE	A214604	001	Mar 08, 2021	Mar	CAHN
	AB				EQ 1% BASE	A214604	001	Mar 08, 2021	Feb	NEWA
>A>	AB			PERRIGO UK FINCO	EQ 1% BASE	A214604	001	Mar 08, 2021	Mar	CAHN

SOLUTION; TOPICAL

CLEOCIN T

	+	@		PFIZER	EQ 1% BASE	N050537	001		Feb	CAHN
	+	@		PHARMACIA AND UPJOHN	EQ 1% BASE	N050537	001		Jan	DISC

SOLUTION;TOPICAL
CLINDAMYCIN PHOSPHATE

AT	!	PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995	Jan CHRS
----	---	------------------	------------	---------	-----	--------------	----------

SUPPOSITORY;VAGINAL
CLEOCIN

	+	PFIZER	100MG	N050767	001	Aug 13, 1999	Feb CAHN
--	---	--------	-------	---------	-----	--------------	----------

SWAB;TOPICAL
CLEOCIN

>D>								
>D>	AT	+	PFIZER	EQ 1% BASE	N050537	002	Feb 22, 1994	Mar DISC
>A>			@	EQ 1% BASE	N050537	002	Feb 22, 1994	Mar DISC
	AT	+		EQ 1% BASE	N050537	002	Feb 22, 1994	Feb CAHN

CLINDAMYCIN PHOSPHATE

>D>	AT		PERRIGO NEW YORK	EQ 1% BASE	A065049	001	May 25, 2000	Mar CHRS
>A>	AT	!		EQ 1% BASE	A065049	001	May 25, 2000	Mar CHRS

CLOBAZAM

TABLET;ORAL
CLOBAZAM

>D>	AB		LANNETT CO INC	10MG	A212092	001	Oct 30, 2019	Mar DISC
>A>			@	10MG	A212092	001	Oct 30, 2019	Mar DISC
>D>	AB			20MG	A212092	002	Oct 30, 2019	Mar DISC
>A>			@	20MG	A212092	002	Oct 30, 2019	Mar DISC

CLOBETASOL PROPIONATE

CREAM;TOPICAL
CLOBETASOL PROPIONATE

>A>	AB1		GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021	Mar NEWA
-----	-----	--	-------------------	-------	---------	-----	--------------	----------

IMPOYZ

>D>		+	ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017	Mar CAHN
>A>		+	PRIMUS PHARMS	0.025%	N209483	001	Nov 28, 2017	Mar CAHN

OINTMENT;TOPICAL
CLOBETASOL PROPIONATE

		@	TORRENT	0.05%	A212926	001	Oct 25, 2019	Jan DISC
--	--	---	---------	-------	---------	-----	--------------	----------

SHAMPOO;TOPICAL
CLOBETASOL PROPIONATE

>A>	AB		TARO PHARMS	0.05%	A214867	001	Mar 25, 2021	Mar NEWA
-----	----	--	-------------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL
CLOBETASOL PROPIONATE

	AT		PRINSTON INC	0.05%	A213139	001	Feb 08, 2021	Jan NEWA
--	----	--	--------------	-------	---------	-----	--------------	----------

CLOFARABINE

SOLUTION;INTRAVENOUS
CLOFARABINE

AP			MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jan CAHN
>D>	AP		NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Mar DISC
>A>			@	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Mar DISC

CLONIDINE

SYSTEM;TRANSDERMAL
CATAPRES-TTS-1

AB	+	LAVIPHARM	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan CAHN
AB	+	TECHNOMED	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan CAHN

CATAPRES-TTS-2

AB	+	LAVIPHARM	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan CAHN
AB	+	TECHNOMED	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan CAHN

CATAPRES-TTS-3

AB	+	LAVIPHARM	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan CAHN
AB	+	TECHNOMED	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
CLONIDINE HYDROCHLORIDE

>D>	AP		HIKMA FARMACEUTICA	5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Mar CHRS
>A>	AP	!		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Mar CHRS

DURACLON

>D>	AP	+	MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999	Mar DISC
>A>			@	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999	Mar DISC

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Feb	CMFD
AB		EQ 300MG BASE	A213351	002	Jul 17, 2020	Feb	CMFD

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

AB	AUROLIFE PHARMA LLC	3.75MG	A071858	002	Jul 17, 1987	Jan	CAHN
AB		7.5MG	A071858	003	Jul 17, 1987	Jan	CAHN
AB	!	15MG	A071858	001	Jul 17, 1987	Jan	CAHN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	AKORN	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014	Feb	CAHN
----	-------	-------------------------------	---------	-----	--------------	-----	------

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

COLESEVELAM HYDROCHLORIDE

	GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Feb	CTEC
@	WATSON LABS INC	1.875GM/PACKET	A202178	001	Sep 01, 2020	Feb	DISC
@		3.75GM/PACKET	A202178	002	Sep 01, 2020	Feb	DISC

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

@ WATSON LABS INC 625MG

A200830 001 Sep 02, 2020 Feb DISC

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

AB	+ PFIZER	5GM/SCOOPFUL	N017563	003	Sep 22, 1995	Feb	CAHN
AB	+!	5GM/PACKET	N017563	004	Sep 22, 1995	Feb	CAHN
	FLAVORED COLESTID						
	+ PFIZER	5GM/PACKET	N017563	001		Feb	CAHN
	+!	5GM/SCOOPFUL	N017563	002		Feb	CAHN

TABLET; ORAL

COLESTID

AB	+! PFIZER	1GM	N020222	001	Jul 19, 1994	Feb	CAHN
----	-----------	-----	---------	-----	--------------	-----	------

CROTAMITON

CREAM; TOPICAL

EURAX

+ @ JOURNEY 10%

N006927 001 Jan CAHN

LOTION; TOPICAL

EURAX

AT	+! JOURNEY	10%	N009112	003		Jan	CAHN
----	------------	-----	---------	-----	--	-----	------

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

SOLUTION; INTRAVENOUS

TRALEMENT

+!	AM REGENT	(1ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML	N209376	001	Jul 02, 2020	Jan	CPOT
+!		(5ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML	N209376	002	Dec 02, 2020	Jan	NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	QUAGEN	4MG	A212491	001	Feb 24, 2021	Feb	NEWA
----	--------	-----	---------	-----	--------------	-----	------

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AP	AUROMEDICS PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CAHN
AP	MEITHEAL	0.5MG/VIAL	A213463	001	Nov 13, 2020	Feb	CAHN

>A>	<u>DASIGLUCAGON HYDROCHLORIDE</u>							
>A>	SOLUTION;SUBCUTANEOUS							
>A>	ZEGALOGUE							
>A>	+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Mar NEWA	
>A>	ZEGALOGUE (AUTOINJECTOR)							
>A>	+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Mar NEWA	
	<u>DEFERASIROX</u>							
	GRANULE;ORAL							
	DEFERASIROX							
AB		AMNEAL	180MG	A214194	001	Feb 09, 2021	Jan NEWA	
AB			360MG	A214194	002	Feb 09, 2021	Jan NEWA	
AB		AUCTA	90MG	A214559	001	Mar 09, 2021	Feb NEWA	
AB			180MG	A214559	002	Mar 09, 2021	Feb NEWA	
AB			360MG	A214559	003	Mar 09, 2021	Feb NEWA	
>A>	AB	MSN	180MG	A214650	001	Mar 17, 2021	Mar NEWA	
>A>	AB		360MG	A214650	002	Mar 17, 2021	Mar NEWA	
	<u>DEFERIPRONE</u>							
	TABLET;ORAL							
	DEFERIPRONE							
>A>	AB	HIKMA	500MG	A213239	001	Mar 29, 2021	Mar NEWA	
	FERRIPROX							
>D>		+!	CHIESI	500MG	N021825	001	Oct 14, 2011	Mar CTEC
>A>	AB	+!		500MG	N021825	001	Oct 14, 2011	Mar CTEC
	<u>DEOXYCHOLIC ACID</u>							
	SOLUTION;SUBCUTANEOUS							
>A>	DEOXYCHOLIC ACID							
>A>	AP	SLAYBACK PHARMA LLC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Mar NFTG	
	<u>DESIPRAMINE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	NORPRAMIN							
AB	+	VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Feb CAHN	
AB	+		25MG	N014399	001		Feb CAHN	
AB	+		50MG	N014399	003		Feb CAHN	
AB	+		75MG	N014399	004		Feb CAHN	
AB	+!		100MG	N014399	005		Feb CAHN	
AB	+		150MG	N014399	006		Feb CAHN	
	<u>DESMOPRESSIN ACETATE</u>							
	SPRAY, METERED;NASAL							
	NOCTIVA							
	+	@	ROIVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Feb CAHN
	+	@		0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Feb CAHN
	<u>DESONIDE</u>							
	GEL;TOPICAL							
	DESONATE							
>D>	AB	+!	LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Mar DISC
>A>		+	@	0.05%	N021844	001	Oct 20, 2006	Mar DISC
	DESONIDE							
>D>	AB		CINTEX SVCS	0.05%	A202470	001	May 11, 2020	Mar CHRS
>A>		!		0.05%	A202470	001	May 11, 2020	Mar CHRS
	<u>DEXRAZOXANE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	DEXRAZOXANE HYDROCHLORIDE							
AP		AUROMEDICS PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Jan CAHN	
AP			EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Jan CAHN	
	ZINECARD							
>A>	AP	+!	PFIZER	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Mar CAHN
>A>	AP	+!		EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Mar CAHN
>D>	AP	+!	PHARMACIA AND UPJOHN	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Mar CAHN
>D>	AP	+!		EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Mar CAHN

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

>D>	AP	FRESENIUS KABI USA	5GM/100ML;75MG/100ML	A212346	001	Sep 10, 2020	Mar	DISC
>A>		@	5GM/100ML;75MG/100ML	A212346	001	Sep 10, 2020	Mar	DISC
			DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%					
>D>	AP	FRESENIUS KABI USA	5GM/100ML;150MG/100ML	A212346	002	Sep 10, 2020	Mar	DISC
>A>		@	5GM/100ML;150MG/100ML	A212346	002	Sep 10, 2020	Mar	DISC
			DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER					
>D>	AP	+ BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003		Mar	CTEC
>A>		+	5GM/100ML;224MG/100ML	N017634	003		Mar	CTEC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Feb	NEWA
			POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Feb	NEWA
			POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Feb	NFTG
			POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP		FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Feb	NEWA
			POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP		FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Feb	NEWA
			POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP		FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Feb	NFTG

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

		@ FRESENIUS KABI USA	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	Feb	DISC
		+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001		Feb	CTEC
>D>			DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
>D>	AP	FRESENIUS KABI USA	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	Mar	DISC
>A>		@	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	Mar	DISC
>D>			DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
>D>	AP	FRESENIUS KABI USA	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	Mar	DISC
>A>		@	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	Mar	DISC

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

>D>	AB	TARO	3%	A206298	001	Apr 28, 2016	Mar	CHRS
>A>	AB	!	3%	A206298	001	Apr 28, 2016	Mar	CHRS
			SOLARAZE					
>D>	AB	+! FOUGERA PHARMS	3%	N021005	001	Oct 16, 2000	Mar	DISC
>A>		+ @	3%	N021005	001	Oct 16, 2000	Mar	DISC

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT		AKORN	1.5%	A206655	001	Jan 28, 2021	Jan	NEWA
			TABLET, DELAYED RELEASE; ORAL					
			DICLOFENAC SODIUM					
		@ MICRO LABS	50MG	A074986	001	Feb 26, 1999	Feb	CAHN
		@	75MG	A074986	002	Feb 26, 1999	Feb	CAHN

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

		@ SANDOZ	EQ 125MG BASE	A061454	002		Jan	DISC
		@	EQ 250MG BASE	A061454	001		Jan	DISC
		@	EQ 500MG BASE	A061454	003		Jan	DISC
		TEVA	EQ 250MG BASE	A062286	001	Jun 03, 1982	Jan	CTEC
		!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Jan	CTEC
AB		!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Jan	CHRS

DIRANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL
DIRANOSINE

@ AUROBINDO PHARMA	125MG	A 090094	001	Sep 24, 2008	Jan	DISC
@	200MG	A 090094	002	Sep 24, 2008	Jan	DISC
@	250MG	A 090094	003	Sep 24, 2008	Jan	DISC
@	400MG	A 090094	004	Sep 24, 2008	Jan	DISC

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION
DIHYDROERGOTAMINE MESYLATE

AP	PROVEPHARM SAS	1MG/ML	A 212046	001	Jan 07, 2020	Jan	CAHN
----	----------------	--------	----------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

>A>	AB1	GLENMARK PHARMS LTD	60MG	A 212317	001	Mar 22, 2021	Mar	NEWA
>A>	AB1		90MG	A 212317	002	Mar 22, 2021	Mar	NEWA
>A>	AB1		120MG	A 212317	003	Mar 22, 2021	Mar	NEWA
>D>		MYLAN	60MG	A 074910	001	May 02, 1997	Mar	CTEC
>A>	AB1		60MG	A 074910	001	May 02, 1997	Mar	CTEC
>D>			90MG	A 074910	002	May 02, 1997	Mar	CTEC
>A>	AB1		90MG	A 074910	002	May 02, 1997	Mar	CTEC
>D>	BC	!	120MG	A 074910	003	May 02, 1997	Mar	CTEC
>A>	AB1	!	120MG	A 074910	003	May 02, 1997	Mar	CTEC

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE

@ INTL MEDICATION	5MG/ML	A 075749	001	Nov 21, 2001	Jan	DISC
-------------------	--------	----------	-----	--------------	-----	------

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

>A>	AB	PHARMATHEN	120MG	A 210436	001	Mar 26, 2021	Mar	NEWA
>A>	AB		240MG	A 210436	002	Mar 26, 2021	Mar	NEWA
		@ ZYDUS PHARMS	120MG	A 210538	001	Sep 24, 2020	Feb	DISC
		@	240MG	A 210538	002	Sep 24, 2020	Feb	DISC

DINOPROSTONE

GEL; ENDOCERVICAL
PREPIDIL

+!	PFIZER	0.5MG/3GM	N 019617	001	Dec 09, 1992	Jan	CAHN
----	--------	-----------	----------	-----	--------------	-----	------

SUPPOSITORY; VAGINAL
PROSTIN E2

+!	PFIZER	20MG	N 017810	001		Jan	CAHN
----	--------	------	----------	-----	--	-----	------

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	OXFORD PHARMS	25MG	A 040542	001	Apr 21, 2006	Jan	CMFD
AB		50MG	A 040542	002	Apr 21, 2006	Jan	CMFD
AB		75MG	A 040542	003	Apr 21, 2006	Jan	CMFD

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

@ MAYNE PHARMA	EQ 100MG BASE	A 070173	001	May 31, 1985	Feb	DISC
@	EQ 150MG BASE	A 070173	002	May 31, 1985	Feb	DISC

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM

>A>	AB	AMTA	EQ 250MG VALPROIC ACID	A 214462	001	Mar 15, 2021	Mar	NEWA
>A>	AB		EQ 500MG VALPROIC ACID	A 214462	002	Mar 15, 2021	Mar	NEWA

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

AP	HIKMA	20MG/ML (20MG/ML)	A 204490	001	Jan 14, 2021	Jan	NEWA
AP		80MG/4ML (20MG/ML)	A 204490	002	Jan 14, 2021	Jan	NEWA
AP	SHILPA	20MG/ML (20MG/ML)	N 205934	001	Dec 22, 2015	Jan	CAHN
AP		80MG/4ML (20MG/ML)	N 205934	002	Dec 22, 2015	Jan	CAHN

INJECTABLE; INJECTION
DOCETAXEL

AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan CAHN
----	--	---------------------	---------	-----	--------------	----------

DOFETILIDECAPSULE; ORAL
DOFETILIDE

	@ RICONPHARMA LLC	0.125MG	A212410	001	Dec 27, 2019	Feb DISC
	@	0.25MG	A212410	002	Dec 27, 2019	Feb DISC
	@	0.5MG	A212410	003	Dec 27, 2019	Feb DISC

DOLASETRON MESYLATEINJECTABLE; INJECTION
ANZEMET

+ @	VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Feb CAHN
+ @		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Feb CAHN
@		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Feb CAHN

TABLET; ORAL
ANZEMET

+ @	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997	Feb CAHN
+ @		100MG	N020623	002	Sep 11, 1997	Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

AT	FDC LTD	EQ 2% BASE; EQ 0.5% BASE	A205295	001	Jun 13, 2019	Feb CMFD
----	---------	--------------------------	---------	-----	--------------	----------

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

>A>	AB	APPCO	EQ 10MG BASE	A214908	001	Apr 01, 2021	Mar NEWA
>A>	AB		EQ 25MG BASE	A214908	002	Apr 01, 2021	Mar NEWA
>A>	AB		EQ 50MG BASE	A214908	003	Apr 01, 2021	Mar NEWA
>A>	AB		EQ 75MG BASE	A214908	004	Apr 01, 2021	Mar NEWA
>A>	AB		EQ 100MG BASE	A214908	005	Apr 01, 2021	Mar NEWA
	AB	LEADING PHARMA LLC	EQ 10MG BASE	A211619	001	Mar 09, 2021	Feb NEWA
	AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Feb NEWA
	AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Feb NEWA
	AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Feb NEWA
	AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Feb NEWA
	AB		EQ 150MG BASE	A211618	001	Mar 01, 2021	Feb NEWA
		@ UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04, 2020	Feb DISC
		@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Feb DISC
		@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb DISC
		@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb DISC
		@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb DISC

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

	@	PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan DISC
	@		EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan DISC
AB		RK PHARMA	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan CAHN
AB			EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

	@	MYLAN	EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan DISC
AB			EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan NEWA
	@		EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan DISC
AB			EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan NEWA
	@		EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan DISC
AB			EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan NEWA

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB		ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb NEWA
----	--	-------	---------------	---------	-----	--------------	----------

DROXIDOPACAPSULE;ORAL
DROXIDOPA

AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214391	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214391	003	Feb 18, 2021	Feb	NFTG
AB	ALKEM LABS LTD	100MG	A213911	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213911	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213911	003	Feb 18, 2021	Feb	NFTG
AB	ANNORA	300MG	A211726	001	Feb 18, 2021	Feb	NFTG
AB	AUROBINDO PHARMA LTD	100MG	A214387	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214387	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214387	003	Feb 18, 2021	Feb	NFTG
AB	HIKMA	100MG	A212835	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A212835	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A212835	003	Feb 18, 2021	Feb	NFTG
AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211652	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211652	003	Feb 18, 2021	Feb	NFTG
AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211741	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211741	003	Feb 18, 2021	Feb	NFTG
AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214017	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214017	003	Feb 18, 2021	Feb	NFTG
AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214384	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214384	003	Feb 18, 2021	Feb	NFTG
AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213661	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213661	003	Feb 18, 2021	Feb	NFTG
AB	TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213162	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213162	003	Feb 18, 2021	Feb	NFTG
AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211818	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211818	003	Feb 18, 2021	Feb	NFTG

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB	SUNSHINE	EQ 20MG BASE	A212328	001	Feb 11, 2021	Feb	NEWA
AB		EQ 30MG BASE	A212328	002	Feb 11, 2021	Feb	NEWA
AB		EQ 60MG BASE	A212328	003	Feb 11, 2021	Feb	NEWA

ECONAZOLE NITRATEAEROSOL, FOAM;TOPICAL
ECOZA

+!	RESILIA PHARMS	1%	N205175	001	Oct 24, 2013	Feb	CAHN
----	----------------	----	---------	-----	--------------	-----	------

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET;ORAL
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
+ @ AUROBINDO PHARMA LTD 600MG;300MG;300MG

N022343	001	Aug 15, 2018	Feb	DISC
---------	-----	--------------	-----	------

EFINACONAZOLESOLUTION;TOPICAL
EFINACONAZOLE

>A>	AB	AUROBINDO PHARMA LTD	10%	A212066	001	Mar 29, 2021	Mar	NEWA
		@ PERRIGO PHARMA INTL	10%	A211851	001	Dec 16, 2020	Jan	DISC
	AB	TEVA PHARMS USA	10%	A211827	001	Dec 16, 2020	Feb	CTEC
		JUBLIA						
	AB	+! BAUSCH	10%	N203567	001	Jun 06, 2014	Feb	CTEC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET;ORAL
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>A>	AB	CIPLA	200MG;300MG	A090958	001	Apr 02, 2021	Mar	NEWA
	AB	LAURUS LABS LTD	200MG;300MG	A212114	001	Jul 26, 2019	Jan	CMFD
	AB	MACLEODS PHARMS LTD	200MG;300MG	A203442	001	May 15, 2020	Feb	CMFD
	AB	MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb	CMFD
	AB	STRIDES PHARMA	200MG;300MG	A091055	001	Jan 13, 2021	Jan	NEWA

EPLERENONE

TABLET; ORAL

EPLERENONE

@	PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Feb	DISC
@		50MG	A212765	002	Aug 10, 2020	Feb	DISC

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

AP2	SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb	CTEC
AP		EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Jan	NFTG
AP2		EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Feb	CTEC
AP		EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Jan	NFTG
AP1	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Feb	CTEC
AP1		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Feb	CTEC

FLOLAN

AP1	+	GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N020444	001	Sep 20, 1995	Feb	CTEC
AP1	+		EQ 1.5MG BASE/VIAL	N020444	002	Sep 20, 1995	Feb	CTEC

VELETRI

AP2	+	ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb	CAHN
AP2	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb	CAHN
AP2	+	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb	CHRS
AP2	+		EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb	CTEC
AP2	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb	CTEC

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

AA	+	VALIDUS PHARMS	50,000 IU	N003444	001		Feb	CAHN
----	---	----------------	-----------	---------	-----	--	-----	------

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

>A>	AP	GLAND PHARMA LTD	EQ 1GM BASE/VIAL	A212040	001	Mar 26, 2021	Mar	NEWA
-----	----	------------------	------------------	---------	-----	--------------	-----	------

ERYTHROMYCIN

TABLET; ORAL

ERYTHROMYCIN

AB	TEVA PHARMS USA INC	250MG	A214549	001	Feb 11, 2021	Feb	NEWA
AB		500MG	A214549	002	Feb 11, 2021	Feb	NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AB	ETHYPHARM	EQ 20MG BASE	A090841	001	Mar 31, 2021	Mar	NEWA
>A>	AB		EQ 40MG BASE	A090841	002	Mar 31, 2021	Mar	NEWA
>A>	AB	GRAVITI PHARMS	EQ 20MG BASE	A213486	001	Mar 19, 2021	Mar	NEWA
>A>	AB		EQ 40MG BASE	A213486	002	Mar 19, 2021	Mar	NEWA
AB	INDCHEMIE HEALTH	EQ 20MG BASE	A210559	001	Feb 26, 2021	Feb	NEWA	
AB		EQ 40MG BASE	A210559	002	Feb 26, 2021	Feb	NEWA	

ESTRADIOL

INSERT, EXTENDED RELEASE; VAGINAL

ESTRING

+	PFIZER	0.0075MG/24HR	N020472	001	Apr 26, 1996	Jan	CAHN
---	--------	---------------	---------	-----	--------------	-----	------

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

>A>	@	PFIZER	1MG/ML	A085470	001		Mar	CAHN
>A>	@		3MG/ML	A085470	002		Mar	CAHN
>A>	!		5MG/ML	A085470	003		Mar	CAHN
>D>	@	PHARMACIA AND UPJOHN	1MG/ML	A085470	001		Mar	CAHN
>D>	@		3MG/ML	A085470	002		Mar	CAHN
>D>	!		5MG/ML	A085470	003		Mar	CAHN

ESTROPIPATE

TABLET;ORAL

OGEN .625

@ PFIZER

0.75MG

A 083220 001

Jan CAHN

OGEN 1.25

@ PFIZER

1.5MG

A 083220 002

Jan CAHN

OGEN 2.5

@ PFIZER

3MG

A 083220 003

Jan CAHN

OGEN 5

PFIZER

6MG

A 083220 004

Jan CAHN

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

@ NOSTRUM LABS INC

1MG

A 203087 001 May 08, 2019

Jan CAHN

@

2MG

A 203087 002 May 08, 2019

Jan CAHN

@

3MG

A 203087 003 May 08, 2019

Jan CAHN

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ETHINYL ESTRADIOL; ETONOGESTREL

AB TEVA PHARMS USA INC

0.015MG/24HR;0.12MG/24HR

A 204305 001 Jan 13, 2021

Jan NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB AMNEAL

0.035MG/24HR;0.15MG/24HR

A 213950 001 Feb 25, 2021

Feb NEWA

XULANE

AB ! MYLAN TECHNOLOGIES

0.035MG/24HR;0.15MG/24HR

A 200910 001 Apr 16, 2014

Feb CTEC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

GEMMILY

>D> AB CHEMO RESEARCH SL

0.02MG;1MG

A 213317 001 Nov 09, 2020

Mar CAHN

>A> AB XIROMED

0.02MG;1MG

A 213317 001 Nov 09, 2020

Mar CAHN

EVEROLIMUS

TABLET;ORAL

AFINITOR

AB + NOVARTIS

10MG

N 022334 002 Mar 30, 2009

Feb CTEC

EVEROLIMUS

@ BIOCON PHARMA

2.5MG

A 214182 001 Feb 11, 2021

Feb DISC

AB

2.5MG

A 214182 001 Feb 11, 2021

Feb NEWA

@

5MG

A 214182 002 Feb 11, 2021

Feb DISC

AB

5MG

A 214182 002 Feb 11, 2021

Feb NEWA

@

7.5MG

A 214182 003 Feb 11, 2021

Feb DISC

AB

7.5MG

A 214182 003 Feb 11, 2021

Feb NEWA

@

10MG

A 214182 004 Feb 11, 2021

Feb DISC

AB

10MG

A 214182 004 Feb 11, 2021

Feb NEWA

AB BRECKENRIDGE

2.5MG

A 205426 001 Mar 05, 2021

Feb NEWA

AB

5MG

A 205426 002 Mar 05, 2021

Feb NEWA

AB

7.5MG

A 205426 003 Mar 05, 2021

Feb NEWA

AB

10MG

A 205426 004 Mar 05, 2021

Feb NEWA

EXEMESTANE

TABLET;ORAL

AROMASIN

>A> AB +! PFIZER

25MG

N 020753 001 Oct 21, 1999

Mar CAHN

>D> AB +! PHARMACIA AND UPJOHN

25MG

N 020753 001 Oct 21, 1999

Mar CAHN

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON

+ @ ASTRAZENECA AB

2MG/VIAL

N 022200 001 Jan 27, 2012

Feb DISC

BYDUREON PEN

+ @ ASTRAZENECA AB

2MG

N 022200 002 Feb 28, 2014

Feb DISC

EZETIMIBETABLET; ORAL
ZETIA

AB	+	ORGANON	10MG	N021445	001	Oct 25, 2002	Feb CAHN
----	---	---------	------	---------	-----	--------------	----------

>A> EZETIMIBE; ROSUVASTATIN CALCIUM>A> TABLET; ORAL
>A> ROSZET

>A>	+	ALThERA PHARMS	10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar NEWA
>A>	+		10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar NEWA
>A>	+		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar NEWA
>A>	+		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar NEWA
>A>	+		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar NEWA
>A>	+		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar NEWA
>A>	+		10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar NEWA
>A>	+		10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar NEWA

EZETIMIBE; SIMVASTATINTABLET; ORAL
EZETIMIBE AND SIMVASTATIN

	@	MYLAN	10MG;10MG	A200082	001	Dec 17, 2020	Jan DISC
	@		10MG;20MG	A200082	002	Dec 17, 2020	Jan DISC
	@		10MG;40MG	A200082	003	Dec 17, 2020	Jan DISC
	@		10MG;80MG	A200082	004	Dec 17, 2020	Jan DISC
		VYTORIN					
AB	+	ORGANON	10MG;10MG	N021687	001	Jul 23, 2004	Feb CAHN
AB	+		10MG;20MG	N021687	002	Jul 23, 2004	Feb CAHN
AB	+		10MG;40MG	N021687	003	Jul 23, 2004	Feb CAHN
AB	+		10MG;80MG	N021687	004	Jul 23, 2004	Feb CAHN

FAMOTIDINEFOR SUSPENSION; ORAL
FAMOTIDINE

AB		AKORN	40MG/5ML	A201995	001	May 30, 2014	Feb CAHN
----	--	-------	----------	---------	-----	--------------	----------

FENOFIBRATETABLET; ORAL
FENOFIBRATE

AB		AUSTARPHARMA	48MG	A208476	001	Feb 10, 2021	Jan NEWA
AB			145MG	A208476	002	Feb 10, 2021	Jan NEWA

FENOPROFEN CALCIUMCAPSULE; ORAL
FENOPROFEN CALCIUM

	@	RISING	EQ 200MG BASE	A072394	001	Oct 17, 1988	Jan CAHN
	@		EQ 300MG BASE	A072395	001	Oct 17, 1988	Jan CAHN

FENTANYL CITRATEINJECTABLE; INJECTION
FENTANYL CITRATE

>D>	AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Mar DISC
>A>		@	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Mar DISC

FERUMOXYTOLSOLUTION; INTRAVENOUS
FERAHEME

>D>	AB	+	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Mar CAHN
>A>	AB	+	COVIS	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Mar CAHN
			FERUMOXYTOL					
AB			SANDOZ INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	A206604	001	Jan 15, 2021	Jan NFTG

FINGOLIMOD HYDROCHLORIDECAPSULE; ORAL
FINGOLIMOD HYDROCHLORIDE

AB		DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Feb NEWA	
		@ MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan DISC	
AB			EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan NEWA	
>D>	AB		ZYDUS PHARMS	EQ 0.5MG BASE	A207994	001	Oct 14, 2020	Mar DISC
>A>			@	EQ 0.5MG BASE	A207994	001	Oct 14, 2020	Mar DISC

FLECAINIDE ACETATETABLET; ORAL
TAMBOCOR

+ @	CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jan	DISC
+ @		100MG	N018830	001	Oct 31, 1985	Jan	DISC
+ @		150MG	N018830	003	Jun 03, 1988	Jan	DISC

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

>A>	AP	CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	Mar	NEWA
		NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Jan	CAHN
	AP	PHARMALOGIC HLDGS	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan	CAHN
>D>		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar	CTEC
>A>	AP		20-500mCi/ML	A204546	001	Apr 07, 2015	Mar	CTEC

FLUMAZENILINJECTABLE; INJECTION
FLUMAZENIL

>D>		@ BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Mar	CMFD
>A>	AP		0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Mar	CMFD
>D>		@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Mar	CMFD
>A>	AP		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Mar	CMFD

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

>A>	AT	SOLARIS PHARMA CORP	0.01%	A212760	001	Apr 02, 2021	Mar	NEWA
>A>	AT		0.01%	A212761	001	Apr 02, 2021	Mar	NEWA

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

>A>	AT	SOLARIS PHARMA CORP	0.01%	A212762	001	Apr 02, 2021	Mar	NEWA
	AT	TASMAN PHARMA	0.01%	A213264	001	Feb 05, 2021	Jan	NEWA

FLUOROURACILINJECTABLE; INJECTION
FLUOROURACIL

>D>		@ NOVAST LABS	500MG/10ML (50MG/ML)	A209271	001	Dec 11, 2019	Mar	CPOT
>A>		@	5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	Mar	CPOT

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

@	ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020	Feb	DISC
@		EQ 20MG BASE	A202729	002	Aug 27, 2020	Feb	DISC
@		EQ 40MG BASE	A202729	003	Aug 27, 2020	Feb	DISC

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB1	TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016	Mar	CHRS
>A>			EQ 10MG BASE	A206937	001	Oct 21, 2016	Mar	CHRS
>D>	AB1		EQ 20MG BASE	A206937	002	Oct 21, 2016	Mar	CHRS
>A>	!		EQ 20MG BASE	A206937	002	Oct 21, 2016	Mar	CHRS
>D>		SARAFEM						
>D>	AB1	+ APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Mar	DISC
>A>		+ @	EQ 10MG BASE	N021860	001	May 19, 2006	Mar	DISC
>D>	AB1	+!	EQ 20MG BASE	N021860	003	May 19, 2006	Mar	DISC
>A>		+ @	EQ 20MG BASE	N021860	003	May 19, 2006	Mar	DISC

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

@	UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jan	DISC
---	-------------------	------	---------	-----	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB		CEROVENE INC	1MG	A214534	001	Jan 07, 2021	Jan	NEWA
AB			2.5MG	A214534	002	Jan 07, 2021	Jan	NEWA
AB			5MG	A214534	003	Jan 07, 2021	Jan	NEWA
AB			10MG	A214534	004	Jan 07, 2021	Jan	NEWA
AB		NOVITIUM PHARMA	1MG	A214674	001	Mar 01, 2021	Feb	NEWA

TABLET;ORAL

	FLUPHENAZINE HYDROCHLORIDE						
AB		2.5MG	A214674	002	Mar 01, 2021	Feb	NEWA
AB		5MG	A214674	003	Mar 01, 2021	Feb	NEWA
AB		10MG	A214674	004	Mar 01, 2021	Feb	NEWA

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLURBIPROFEN SODIUM

!	BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995	Jan	CHRS
		0.03%	A074447	001	Jan 04, 1995	Jan	CTEC
	OCUFEN						
+	@ ALLERGAN	0.03%	N019404	001	Dec 31, 1986	Jan	DISC

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

>D>	AB	!	CIPLA	125MG	A075780	001	Sep 19, 2001	Mar	DISC
>A>		@		125MG	A075780	001	Sep 19, 2001	Mar	DISC
>D>	AB		PAR PHARM	125MG	A075298	001	Sep 18, 2001	Mar	CHRS
>A>		!		125MG	A075298	001	Sep 18, 2001	Mar	CHRS

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

@	BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb	DISC
---	----------------	-------	---------	-----	--------------	-----	------

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

AP		AUROBINDO PHARMA LTD	EQ 150MG BASE/VIAL	A210625	001	Jan 12, 2021	Jan	NEWA
AP		CHIA TAI TIANQING	EQ 150MG BASE/VIAL	A212143	001	Mar 03, 2021	Feb	NEWA
>D>		MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Mar	DISC
>A>		@	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Mar	DISC

FOSCARNET SODIUM

INJECTABLE;INJECTION

FOSCARNET SODIUM

AP		FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Jan	NEWA
AP	+	! CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Jan	CTEC

FOSDENOPTERIN HYDROBROMIDE

POWDER;INTRAVENOUS

NULIBRY

+	!	ORIGIN	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021	Feb	NEWA
---	---	--------	--------------------	---------	-----	--------------	-----	------

FULVESTRANT

INJECTABLE;INTRAMUSCULAR

FULVESTRANT

AO		AUROMEDICS PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Jan	CAHN
----	--	-------------------	---------	---------	-----	--------------	-----	------

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP		ATHENEX INC	10MG/ML	A214766	001	Jan 27, 2021	Jan	NEWA
----	--	-------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

LASIX

AB	+	VALIDUS PHARMS	20MG	N016273	002		Feb	CAHN
AB	+		40MG	N016273	001		Feb	CAHN
AB	+	!	80MG	N016273	003		Feb	CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

@	ZHEJIANG YONGTAI	100MG	A213603	001	Aug 17, 2020	Feb	DISC
@		300MG	A213603	002	Aug 17, 2020	Feb	DISC
@		400MG	A213603	003	Aug 17, 2020	Feb	DISC

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

AT		AKORN	0.5%	A203189	001	Sep 03, 2014	Feb CAHN
----	--	-------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	!	JIANGSU HANSOH PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Feb CHRS
AP	!		EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Feb CHRS
AP		MEITHEAL	200MG/5.26ML (38MG/ML)	A212129	001	Dec 11, 2020	Jan CAHN
AP			1GM/26.3ML (38MG/ML)	A212129	002	Dec 11, 2020	Jan CAHN
AP			2GM/52.6ML (38MG/ML)	A212129	003	Dec 11, 2020	Jan CAHN
		GEMZAR					
	+	@ LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Feb DISC
	+	@	EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Feb DISC

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

AB		ASCENT PHARMS INC	600MG	A214603	001	Jan 13, 2021	Jan NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

GLYBURIDETABLET; ORAL
GLYNASE

AB	+	PFIZER	1.5MG	N020051	001	Mar 04, 1992	Feb CAHN
AB	+		3MG	N020051	002	Mar 04, 1992	Feb CAHN
	+	@	4.5MG	N020051	003	Sep 24, 1993	Feb CAHN
AB	+	!	6MG	N020051	004	Sep 24, 1993	Feb CAHN
		MICRONASE					
	+	@ PFIZER	1.25MG	N017498	001	May 01, 1984	Feb CAHN
		@	2.5MG	N017498	002	May 01, 1984	Feb CAHN
	+	@	5MG	N017498	003	May 01, 1984	Feb CAHN

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP		ATHENEX INC	0.2MG/ML	A210083	001	Feb 21, 2020	Jan CAHN
AP		XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Feb NEWA

GRANISETRON HYDROCHLORIDESOLUTION; ORAL
GRANISOL

	@	INTRA SANA LABS	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jan CAHN
--	---	-----------------	------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDETABLET; ORAL
GUANFACINE HYDROCHLORIDE

AB	!	AMNEAL PHARM	EQ 2MG BASE	A075109	002	Nov 25, 1998	Jan CHRS
	@	MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jan DISC
	@		EQ 2MG BASE	A074796	002	Jan 27, 1997	Jan DISC
AB		UNICHEM	EQ 1MG BASE	A214689	001	Mar 03, 2021	Feb NEWA
AB			EQ 2MG BASE	A214689	002	Mar 03, 2021	Feb NEWA

HALOBETASOL PROPIONATEOINTMENT; TOPICAL
HALOBETASOL PROPIONATE

>D>	AB	!	COSETTE	0.05%	A077721	001	Sep 07, 2006	Mar DISC
>A>		@		0.05%	A077721	001	Sep 07, 2006	Mar DISC
>D>	AB		PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Mar CHRS
>A>	AB	!		0.05%	A076872	001	Dec 16, 2004	Mar CHRS
			ULTRAVATE					
>D>	AB	+	SUN PHARM INDS INC	0.05%	N019968	001	Dec 17, 1990	Mar DISC
>A>		+	@	0.05%	N019968	001	Dec 17, 1990	Mar DISC

HALOPERIDOL LACTATECONCENTRATE; ORAL
HALDOL

>D>		@	ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001		Mar CRLD
>A>		+	@	EQ 2MG BASE/ML	N015922	001		Mar CRLD

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ FRESenius KABI USA 200 UNITS/100ML A212441 001 Jul 24, 2020 Jan DISC

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ FRESenius KABI USA 200 UNITS/100ML A212441 002 Jul 24, 2020 Jan DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

MICROZIDE

>D>	AB	+	!	ALLERGAN	12.5MG	N020504	001	Dec 27, 1996	Mar	CAHN
>A>	AB	+	!	TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Mar	CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

ZESTORETIC

AB	+			ALMATICA	12.5MG; 10MG	N019888	003	Nov 18, 1993	Jan	CAHN
AB	+	!			12.5MG; 20MG	N019888	001	Sep 20, 1990	Jan	CAHN
AB	+	!			25MG; 20MG	N019888	002	Jul 20, 1989	Jan	CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	+			VALIDUS PHARMS	25MG; 50MG	N018303	001	Dec 31, 1984	Feb	CAHN
				+ @	25MG; 100MG	N018303	002	Dec 31, 1984	Feb	CAHN
				+ @	50MG; 100MG	N018303	003	Dec 31, 1984	Feb	CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

AB				ALVOGEN PINE BROOK	20MG	A208269	001	Mar 01, 2021	Feb	NFTG
AB					30MG	A208269	002	Mar 01, 2021	Feb	NFTG
AB					40MG	A208269	003	Mar 01, 2021	Feb	NFTG
AB					60MG	A208269	004	Mar 01, 2021	Feb	NFTG
AB					80MG	A208269	005	Mar 01, 2021	Feb	NFTG
AB					100MG	A208269	006	Mar 01, 2021	Feb	NFTG
AB					120MG	A208269	007	Mar 01, 2021	Feb	NFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB				NOSTRUM LABS INC	5MG; 200MG	A077727	001	Nov 06, 2006	Jan	CAHN
AB					7.5MG; 200MG	A077723	001	Nov 06, 2006	Jan	CAHN
>D>	AB				10MG; 200MG	A077723	002	Nov 06, 2006	Mar	CTEC
>A>					10MG; 200MG	A077723	002	Nov 06, 2006	Mar	CTEC
	AB				10MG; 200MG	A077723	002	Nov 06, 2006	Jan	CAHN
>D>				REPREXAIN						
>D>				AMNEAL PHARMS NY	2.5MG; 200MG	A076642	003	Oct 19, 2007	Mar	DISC
>A>				@	2.5MG; 200MG	A076642	003	Oct 19, 2007	Mar	DISC
>D>	AB				10MG; 200MG	A076642	004	Oct 19, 2007	Mar	DISC
>A>				@	10MG; 200MG	A076642	004	Oct 19, 2007	Mar	DISC

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTISONE

+ @ MERCK EQ 50MG BASE/ML N012052 001 Feb CRLD

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB COSETTE 0.2% A213724 001 Feb 11, 2021 Feb NEWA

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

>D>	AB			LANNETT CO INC	2MG	A077471	002	Dec 09, 2009	Mar	DISC
>A>				@	2MG	A077471	002	Dec 09, 2009	Mar	DISC
>D>	AB				4MG	A077471	003	Dec 09, 2009	Mar	DISC
>A>				@	4MG	A077471	003	Dec 09, 2009	Mar	DISC
>D>	AB				8MG	A077471	001	Dec 09, 2009	Mar	DISC
>A>				@	8MG	A077471	001	Dec 09, 2009	Mar	DISC

HYDROXYPROGESTERONE CAPROATESOLUTION; INTRAMUSCULAR
MAKENA

>D>	AP1	+	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Mar	CAHN
>A>	AP1	+	COVIS	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Mar	CAHN
MAKENA PRESERVATIVE FREE									
>D>	AP	+	AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Mar	CAHN
>A>	AP	+	COVIS	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Mar	CAHN
SOLUTION; SUBCUTANEOUS MAKENA (AUTOINJECTOR)									
>D>		+	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Mar	CAHN
>A>		+	COVIS	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Mar	CAHN

HYDROXYUREATABLET; ORAL
SIKLOS

>D>		+	ADDMEDICA SAS	1GM	N208843	002	Dec 21, 2017	Mar	CHRS
>A>		+		1GM	N208843	002	Dec 21, 2017	Mar	CHRS

HYDROXYZINE HYDROCHLORIDETABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

AB			PRINSTON INC	10MG	A040580	003	May 27, 2005	Feb	CMS1
AB				25MG	A040580	002	May 27, 2005	Feb	CMS1

IBRUTINIBCAPSULE; ORAL
IBRUTINIB

>A>	AB		ZYDUS	70MG	A211344	001	Mar 31, 2021	Mar	NFTG
>A>	AB			140MG	A211344	002	Mar 31, 2021	Mar	NFTG

IBUPROFENTABLET; ORAL
IBUPROFEN

			@ VINTAGE PHARMS	400MG	A071644	001	Feb 01, 1988	Feb	DISC
--	--	--	------------------	-------	---------	-----	--------------	-----	------

IBUTILIDE FUMARATEINJECTABLE; INJECTION
CORVERT

AP		+	PFIZER	0.1MG/ML	N020491	001	Dec 28, 1995	Feb	CAHN
----	--	---	--------	----------	---------	-----	--------------	-----	------

ICOSAPENT ETHYLCAPSULE; ORAL
ICOSAPENT ETHYL

>D>	AB		TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Mar	DISC
>A>			@	500MG	A209525	001	Sep 11, 2020	Mar	DISC
>D>	AB			1GM	A209525	002	Sep 11, 2020	Mar	DISC
>A>			@	1GM	A209525	002	Sep 11, 2020	Mar	DISC
VASCEPA									
>D>	AB	+	AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar	CTEC
>A>		+		500MG	N202057	002	Feb 16, 2017	Mar	CTEC

ILOPROSTSOLUTION; INHALATION
VENTAVIS

		+	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Feb	CAHN
			@	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Feb	CAHN
		+		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Feb	CAHN

IMIQUIMODCREAM; TOPICAL
IMIQUIMOD

AB			TARO	3.75%	A205971	001	Jan 26, 2021	Jan	NFTG
----	--	--	------	-------	---------	-----	--------------	-----	------

INDOMETHACINCAPSULE; ORAL
INDOMETHACIN

			@ JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017	Jan	DISC
			@	50MG	A205215	002	Aug 25, 2017	Jan	DISC

CAPSULE, EXTENDED RELEASE;ORAL
 INDOMETHACIN
 @ AUROBINDO PHARMA LTD 75MG

A204243 001 Dec 27, 2016 Jan DISC

IOPAMIDOL

INJECTABLE; INJECTION
 ISOVUE-300

+! BRACCO 61% N018735 002 Dec 31, 1985 Jan CTEC

ISOVUE-370

+! BRACCO 76% N018735 003 Dec 31, 1985 Jan CTEC

SCANLUX-300

@ SANOCHEMIA CORP USA 61% A090394 001 Jun 18, 2010 Jan DISC

SCANLUX-370

@ SANOCHEMIA CORP USA 76% A090394 002 Jun 18, 2010 Jan DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>D> AP EMCURE PHARMS LTD 40MG/2ML (20MG/ML) A200771 001 Feb 14, 2012 Mar DISC

>A> @ 40MG/2ML (20MG/ML) A200771 001 Feb 14, 2012 Mar DISC

>D> AP 100MG/5ML (20MG/ML) A200771 002 Feb 14, 2012 Mar DISC

>A> @ 100MG/5ML (20MG/ML) A200771 002 Feb 14, 2012 Mar DISC

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP AUROBINDO PHARMA LTD 0.2MG/ML A211864 001 Feb 09, 2021 Jan NEWA

AP MICRO LABS 0.2MG/ML A210845 001 Feb 16, 2021 Feb NEWA

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

>D> AB MYLAN PHARMS INC 10MG A075945 001 Nov 08, 2002 Mar CTEC

>A> AB1 10MG A075945 001 Nov 08, 2002 Mar CTEC

>D> AB 20MG A075945 002 Nov 08, 2002 Mar CTEC

>A> AB1 20MG A075945 002 Nov 08, 2002 Mar CTEC

>D> AB 40MG A075945 003 Nov 08, 2002 Mar CTEC

>A> AB1 40MG A075945 003 Nov 08, 2002 Mar CTEC

CLARAVIS

>D> AB TEVA PHARMS USA 10MG A076356 001 Apr 11, 2003 Mar CTEC

>A> AB1 10MG A076356 001 Apr 11, 2003 Mar CTEC

>D> AB 20MG A076135 002 Apr 11, 2003 Mar CTEC

>A> AB1 20MG A076135 002 Apr 11, 2003 Mar CTEC

>D> AB 30MG A076135 003 May 11, 2006 Mar CTEC

>A> AB1 30MG A076135 003 May 11, 2006 Mar CTEC

>D> AB ! 40MG A076135 001 Apr 11, 2003 Mar CTEC

>A> AB1 ! 40MG A076135 001 Apr 11, 2003 Mar CTEC

ISOTRETINOIN

>A> AB2 ACTAVIS LABS FL 10MG A205063 001 Mar 31, 2021 Mar NFTG

>A> AB2 20MG A205063 002 Mar 31, 2021 Mar NFTG

>A> AB2 25MG A205063 003 Mar 31, 2021 Mar NFTG

>A> AB2 30MG A205063 004 Mar 31, 2021 Mar NFTG

>A> AB2 35MG A205063 005 Mar 31, 2021 Mar NFTG

>A> AB2 40MG A205063 006 Mar 31, 2021 Mar NFTG

>D> AB AMNEAL PHARMS NY 10MG A207792 001 Sep 29, 2017 Mar CTEC

>A> AB1 10MG A207792 001 Sep 29, 2017 Mar CTEC

>D> AB 20MG A207792 002 Sep 29, 2017 Mar CTEC

>A> AB1 20MG A207792 002 Sep 29, 2017 Mar CTEC

>D> AB 30MG A207792 003 Sep 29, 2017 Mar CTEC

>A> AB1 30MG A207792 003 Sep 29, 2017 Mar CTEC

>D> AB 40MG A207792 004 Sep 29, 2017 Mar CTEC

>A> AB1 40MG A207792 004 Sep 29, 2017 Mar CTEC

MYORISAN

>D> AB DOUGLAS PHARMS 10MG A076485 001 Jan 19, 2012 Mar CTEC

>A> AB1 10MG A076485 001 Jan 19, 2012 Mar CTEC

>D> AB 20MG A076485 002 Jan 19, 2012 Mar CTEC

>A> AB1 20MG A076485 002 Jan 19, 2012 Mar CTEC

>D> AB 30MG A076485 004 Aug 25, 2015 Mar CTEC

>A> AB1 30MG A076485 004 Aug 25, 2015 Mar CTEC

>D> AB 40MG A076485 003 Jan 19, 2012 Mar CTEC

>A> AB1 40MG A076485 003 Jan 19, 2012 Mar CTEC

CAPSULE;ORALZENATANE

>D>	AB	DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar CTEC
>A>	AB1		10MG	A202099	001	Mar 25, 2013	Mar CTEC
>D>	AB		20MG	A202099	002	Mar 25, 2013	Mar CTEC
>A>	AB1		20MG	A202099	002	Mar 25, 2013	Mar CTEC
>D>	AB		30MG	A202099	004	Feb 23, 2015	Mar CTEC
>A>	AB1		30MG	A202099	004	Feb 23, 2015	Mar CTEC
>D>	AB		40MG	A202099	003	Mar 25, 2013	Mar CTEC
>A>	AB1		40MG	A202099	003	Mar 25, 2013	Mar CTEC

IVERMECTINTABLET;ORALSTROMEKTOL

		+ @ MERCK SHARP DOHME	6MG	N050742	001	Nov 22, 1996	Feb CRLD
--	--	-----------------------	-----	---------	-----	--------------	----------

KETAMINE HYDROCHLORIDEINJECTABLE;INJECTIONKETAMINE HYDROCHLORIDE

AP		AUROMEDICS PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Jan CAHN
AP			EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Jan CAHN
AP			EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Jan CAHN

KETOCONAZOLETABLET;ORALKETOCONAZOLE

>D>	AB	MYLAN	200MG	A075597	001	Dec 23, 1999	Mar DISC
>A>		@	200MG	A075597	001	Dec 23, 1999	Mar DISC

KETOPROFENCAPSULE;ORALKETOPROFEN@ RISING@

50MG

75MG

A074024 001 Dec 29, 1995 Jan CAHN

A074024 002 Dec 29, 1995 Jan CAHN

KETOROLAC TROMETHAMINEINJECTABLE;INJECTIONKETOROLAC TROMETHAMINE

>D>	AP	HOSPIRA	15MG/ML	A074993	001	Jan 27, 1999	Mar DISC
>A>		@	15MG/ML	A074993	001	Jan 27, 1999	Mar DISC

LABETALOL HYDROCHLORIDEINJECTABLE;INJECTIONLABETALOL HYDROCHLORIDE

>D>		@ BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Mar CMFD
>A>	AP		5MG/ML	A076051	001	Jul 05, 2002	Mar CMFD

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET;ORALLAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

		+ @ AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	Feb DISC
--	--	--------------------------	-------------	---------	-----	--------------	----------

LAMOTRIGINETABLET, ORALLY DISINTEGRATING;ORALLAMOTRIGINE

AB		AJANTA PHARMA LTD	25MG	A213271	001	Jan 19, 2021	Jan NEWA
AB			50MG	A213271	002	Jan 19, 2021	Jan NEWA
AB			100MG	A213271	003	Jan 19, 2021	Jan NEWA
AB			200MG	A213271	004	Jan 19, 2021	Jan NEWA

LANSOPRAZOLETABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORALLANSOPRAZOLE

AB		DR REDDYS LABS LTD	15MG	A210465	001	Feb 01, 2021	Jan NEWA
AB			30MG	A210465	002	Feb 01, 2021	Jan NEWA

LEFLUNOMIDETABLET;ORALLEFLUNOMIDE

>A>	AB	AUROBINDO PHARMA LTD	10MG	A213652	001	Mar 29, 2021	Mar NEWA
>A>	AB		20MG	A213652	002	Mar 29, 2021	Mar NEWA

LETROZOLE

TABLET; ORAL

LETROZOLE

@	APOTEX INC	2.5MG	A091303	001	Apr 19, 2012	Jan	DISC
---	------------	-------	---------	-----	--------------	-----	------

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

AP	AUROBINDO PHARMA LTD	1GM/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Feb	CPOT
AP		1.5GM/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Feb	CPOT
AP	GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb	CPOT
AP		1.5GM/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb	CDFR
AP	+! HQ SPECIALITY PHARMA	1GM/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Feb	CPOT
AP	+!	1.5GM/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Feb	CPOT
AP	NEXUS PHARMS	1GM/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb	CPOT
AP		1.5GM/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb	CPOT

SOLUTION; ORAL

LEVETIRACETAM

AA	AKORN	100MG/ML	A090601	001	Feb 28, 2012	Feb	CAHN
----	-------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

LEVETIRACETAM

>D>	AB	NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011	Mar	DISC
>A>		@	250MG	A090511	001	Aug 18, 2011	Mar	DISC
	AB		250MG	A090511	001	Aug 18, 2011	Jan	CAHN
>D>	AB		500MG	A090511	002	Aug 18, 2011	Mar	DISC
>A>		@	500MG	A090511	002	Aug 18, 2011	Mar	DISC
	AB		500MG	A090511	002	Aug 18, 2011	Jan	CAHN
>D>	AB		750MG	A090511	003	Aug 18, 2011	Mar	DISC
>A>		@	750MG	A090511	003	Aug 18, 2011	Mar	DISC
	AB		750MG	A090511	003	Aug 18, 2011	Jan	CAHN
>D>	AB		1GM	A090511	004	Aug 18, 2011	Mar	DISC
>A>		@	1GM	A090511	004	Aug 18, 2011	Mar	DISC
	AB		1GM	A090511	004	Aug 18, 2011	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

ELEPSIA XR

+	TRIPOINT	1GM	N204417	001	Dec 20, 2018	Jan	CAHN
+!		1.5GM	N204417	002	Dec 20, 2018	Jan	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>D>	AB	NEOPHARMA	5MG	A204323	001	Dec 20, 2016	Mar	DISC
>A>		@	5MG	A204323	001	Dec 20, 2016	Mar	DISC

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

AB	NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Jan	NEWA
AB	! SENTYNL THERAPS INC	3MG	A074278	003	Jun 18, 2018	Jan	CTEC

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

@	DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020	Feb	DISC
---	-----------	-------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

TIROSINT-SOL

+	INSTITUT BIOCHIMIQUE	37.5MCG/ML	N206977	013	Jan 13, 2021	Jan	NEWA
+		44MCG/ML	N206977	014	Jan 13, 2021	Jan	NEWA
+		62.5MCG/ML	N206977	015	Jan 13, 2021	Jan	NEWA

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

XYLOCAINE

+	@ AKORN	2%	N008816	001		Jan	DISC
---	---------	----	---------	-----	--	-----	------

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT	LANNETT CO INC	2%	A040708	001	Feb 27, 2007	Jan	CMFD
----	----------------	----	---------	-----	--------------	-----	------

LINACLOTIDE

	CAPSULE; ORAL						
	LINACLOTIDE						
	@ MYLAN	145MCG	A209564	001	Feb 09, 2021	Feb	DISC
AB		145MCG	A209564	001	Feb 09, 2021	Jan	NFTG
	@	290MCG	A209564	002	Feb 09, 2021	Feb	DISC
AB		290MCG	A209564	002	Feb 09, 2021	Jan	NFTG
	LINZESS						
	+! ALLERGAN	145MCG	N202811	001	Aug 30, 2012	Feb	CTEC
	+	290MCG	N202811	002	Aug 30, 2012	Feb	CTEC

LINCOMYCIN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	LINCOCIN						
AP	+! PFIZER	EQ 300MG BASE/ML	N050317	001		Feb	CAHN
	LINCOMYCIN HYDROCHLORIDE						
>A> AP	PRAXGEN	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Mar	NEWA

LIOTHYRONINE SODIUM

	TABLET; ORAL						
	LIOTHYRONINE SODIUM						
AB	ZYDUS	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Jan	NEWA
AB		EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Jan	NEWA
AB		EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Jan	NEWA

LISINOPRIL

	TABLET; ORAL						
	LISINOPRIL						
AB	YILING	20MG	A208920	001	Mar 04, 2021	Feb	NEWA
AB		30MG	A208920	002	Mar 04, 2021	Feb	NEWA
AB		40MG	A208920	003	Mar 04, 2021	Feb	NEWA

LORAZEPAM

	CONCENTRATE; ORAL						
	LORAZEPAM						
AA	AKORN	2MG/ML	A200169	001	Jan 30, 2012	Feb	CAHN

LOTEPREDNOL ETABONATE

	GEL; OPHTHALMIC						
	LOTEPREDNOL ETABONATE						
AB	AKORN	0.5%	A212080	001	Feb 10, 2021	Jan	NFTG
	SUSPENSION/DROPS; OPHTHALMIC						
	LOTEPREDNOL ETABONATE						
AB	SUN PHARM	0.5%	A212450	001	Feb 26, 2021	Feb	NEWA

LURASIDONE HYDROCHLORIDE

	TABLET; ORAL						
	LURASIDONE HYDROCHLORIDE						
AB	WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021	Jan	NEWA
AB		40MG	A208016	002	Feb 02, 2021	Jan	NEWA
AB		60MG	A208016	003	Feb 02, 2021	Jan	NEWA
AB		80MG	A208016	004	Feb 02, 2021	Jan	NEWA
AB		120MG	A208016	005	Feb 02, 2021	Jan	NEWA

MACITENTAN

	TABLET; ORAL						
	MACITENTAN						
>A> AB	ZYDUS	10MG	A211224	001	Apr 06, 2021	Mar	NFTG

MAGNESIUM SULFATE

	INJECTABLE; INJECTION						
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Feb	CMFD
	MAGNESIUM SULFATE IN PLASTIC CONTAINER						
AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb	CMFD
AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb	CMFD
AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb	CMFD

MEDROXYPROGESTERONE ACETATEINJECTABLE; INJECTION
DEPO-PROVERA

>A>	+	@ PFIZER	100MG/ML	N012541	002			Mar	CAHN
>A>	AB	+	150MG/ML	N020246	001	Oct 29, 1992		Mar	CAHN
>A>		+	400MG/ML	N012541	003			Mar	CAHN
>D>		+ @ PHARMACIA AND UPJOHN	100MG/ML	N012541	002			Mar	CAHN
>D>	AB	+	150MG/ML	N020246	001	Oct 29, 1992		Mar	CAHN
>D>		+	400MG/ML	N012541	003			Mar	CAHN

INJECTABLE; SUBCUTANEOUS
DEPO-SUBQ PROVERA 104

>A>		+	PFIZER	104MG/0.65ML	N021583	001	Dec 17, 2004	Mar	CAHN
>D>		+	PHARMACIA AND UPJOHN	104MG/0.65ML	N021583	001	Dec 17, 2004	Mar	CAHN

TABLET; ORAL
PROVERA

>A>	AB	+	PFIZER	2.5MG	N011839	001		Mar	CAHN
>A>	AB		+	5MG	N011839	003		Mar	CAHN
>A>	AB		+	10MG	N011839	004		Mar	CAHN
>D>	AB	+	PHARMACIA AND UPJOHN	2.5MG	N011839	001		Mar	CAHN
>D>	AB		+	5MG	N011839	003		Mar	CAHN
>D>	AB		+	10MG	N011839	004		Mar	CAHN

MEFENAMIC ACIDCAPSULE; ORAL
MEFENAMIC ACID

>D>	AB		STRIDES PHARMA	250MG	A209209	001	Sep 18, 2020	Mar	DISC
>A>			@	250MG	A209209	001	Sep 18, 2020	Mar	DISC

MELOXICAMCAPSULE; ORAL
MELOXICAM

AB			LUPIN LTD	5MG	A209487	001	Jun 01, 2020	Feb	CTEC
AB			!	10MG	A209487	002	Jun 01, 2020	Feb	CTEC
AB			NOVITIUM PHARMA	5MG	A211398	001	Mar 09, 2021	Feb	NEWA
AB				10MG	A211398	002	Mar 09, 2021	Feb	NEWA

MELPHALANTABLET; ORAL
MELPHALAN

!	ALVOGEN	2MG	A207809	001	Mar 22, 2017	Jan	CAHN
---	---------	-----	---------	-----	--------------	-----	------

MELPHALAN FLUFENAMIDEPOWDER; INTRAVENOUS
PEPAXTO

>D>		+	ONCOPEPTIDES AB	20MG/VIAL	N214383	001	Feb 26, 2021	Mar	CPOT
		+		20MG/VIAL	N214383	001	Feb 26, 2021	Feb	NEWA

MELPHALAN FLUFENAMIDE HYDROCHLORIDEPOWDER; INTRAVENOUS
PEPAXTO

>A>		+	ONCOPEPTIDES AB	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021	Mar	CPOT
-----	--	---	-----------------	-------------------	---------	-----	--------------	-----	------

MELPHALAN HYDROCHLORIDEINJECTABLE; INJECTION
ALKERAN

+	@ APOTEX	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan	DISC
---	----------	-------------------	---------	-----	--------------	-----	------

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
MEMANTINE HYDROCHLORIDE

>A>	AB		YICHANG HUMANWELL	7MG	A211100	001	Apr 02, 2021	Mar	NEWA
>A>	AB			14MG	A211100	002	Apr 02, 2021	Mar	NEWA
>A>	AB			21MG	A211100	003	Apr 02, 2021	Mar	NEWA
>A>	AB			28MG	A211100	004	Apr 02, 2021	Mar	NEWA

MEPERIDINE HYDROCHLORIDEINJECTABLE; INJECTION
DEMEROL

@	VALIDUS PHARMS	25MG/ML	N005010	007		Feb	CAHN
@		50MG/ML	N005010	002		Feb	CAHN
@		75MG/ML	N005010	009		Feb	CAHN

INJECTABLE; INJECTION

	DEMEROL						
	@	100MG/ML		N005010	003		Feb CAHN
	SYRUP; ORAL						
	DEMEROL						
	@ VALIDUS PHARMS	50MG/5ML		N005010	005		Feb CAHN
	TABLET; ORAL						
	DEMEROL						
	+ @ VALIDUS PHARMS	50MG		N005010	001		Feb CAHN
	+ @	100MG		N005010	004		Feb CAHN

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

>D>	AA	ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	Mar CHRS
>A>	AA	!	200MG	A090122	001	Feb 18, 2009	Mar CHRS
>D>	AA		400MG	A090122	002	Feb 18, 2009	Mar CHRS
>A>	AA	!	400MG	A090122	002	Feb 18, 2009	Mar CHRS
>D>	AA	! WATSON LABS	200MG	A083304	001		Mar DISC
>A>		@	200MG	A083304	001		Mar DISC
>D>	AA	!	400MG	A083308	001		Mar DISC
>A>		@	400MG	A083308	001		Mar DISC

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS
VABOMERE

+!	REMPEX	1GM/VIAL; 1GM/VIAL		N209776	001	Aug 29, 2017	Feb CAHN
----	--------	--------------------	--	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

AB3		AJANTA PHARMA LTD	500MG	A213962	001	Mar 09, 2021	Feb NEWA
AB3			1GM	A213962	002	Mar 09, 2021	Feb NEWA
AB3		GRANULES	500MG	A213344	001	Jan 12, 2021	Jan NEWA
AB3			1GM	A213344	002	Jan 12, 2021	Jan NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@	TORRENT PHARMS LTD	500MG; EQ 15MG BASE		A202001	001	Feb 13, 2013	Jan DISC
@		850MG; EQ 15MG BASE		A202001	002	Feb 13, 2013	Jan DISC

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HYDROCHLORIDE

AA		LANNETT CO INC	10MG/ML	A212094	001	Mar 03, 2021	Feb NEWA
----	--	----------------	---------	---------	-----	--------------	----------

METHENAMINE HIPPURATE

TABLET; ORAL

>D>		HIPREX					
>D>	AB	+! VALIDUS PHARMS	1GM	N017681	001		Mar DISC
>A>		+ @	1GM	N017681	001		Mar DISC
	AB	+!	1GM	N017681	001		Feb CAHN
		METHENAMINE HIPPURATE					
>D>	AB	AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Mar CHRS
>A>	AB	!	1GM	A205661	001	Jul 05, 2016	Mar CHRS

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

@	AUROBINDO PHARMA LTD	750MG		A213967	001	Aug 12, 2020	Feb DISC
---	----------------------	-------	--	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

TABLET; ORAL
METHYLERGONOVINE MALEATE

AB		RISING	0.2MG	A211919	001	Jan 15, 2021	Jan NEWA
----	--	--------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	ASCENT PHARMS INC	5MG/5ML	A207417	001	Jan 29, 2021	Jan	NEWA
AA		10MG/5ML	A207417	002	Jan 29, 2021	Jan	NEWA
	@ LANNETT CO INC	5MG/5ML	A207414	001	Dec 16, 2020	Jan	DISC
	@	10MG/5ML	A207414	002	Dec 16, 2020	Jan	DISC

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB	PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	CAHN
----	---------	-----	---------	-----	--------------	-----	------

METOLAZONE

TABLET; ORAL

METOLAZONE

>A>	AB	BAYSHORE PHARMS LLC	2.5MG	A214799	001	Mar 30, 2021	Mar	NEWA
>A>	AB		5MG	A214799	002	Mar 30, 2021	Mar	NEWA
>A>	AB		10MG	A214799	003	Mar 30, 2021	Mar	NEWA
>A>	AB	INNOGENIX	2.5MG	A213827	001	Mar 30, 2021	Mar	NEWA
>A>	AB		5MG	A213827	002	Mar 30, 2021	Mar	NEWA
>A>	AB		10MG	A213827	003	Mar 30, 2021	Mar	NEWA

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	YICHANG HUMANWELL	EQ 100MG TARTRATE	A213854	001	Feb 12, 2021	Feb	NEWA
AB		EQ 200MG TARTRATE	A213854	002	Feb 12, 2021	Feb	NEWA

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

AB	+ VALIDUS PHARMS	50MG	N017963	001		Feb	CAHN
AB	+	100MG	N017963	002		Feb	CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	RICONPHARMA LLC	150MG	A214352	001	Jan 25, 2021	Jan	NEWA
AB		200MG	A214352	002	Jan 25, 2021	Jan	NEWA
AB		250MG	A214352	003	Jan 25, 2021	Jan	NEWA

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

>A>	+!	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021	Mar	NEWA
>A>	+!		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021	Mar	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	2.5MG	A214734	001	Jan 21, 2021	Jan	NEWA
AB		5MG	A214734	002	Jan 21, 2021	Jan	NEWA
AB		10MG	A214734	003	Jan 21, 2021	Jan	NEWA

MIGLITOL

TABLET; ORAL

GLYSET

AB	+!	PFIZER	25MG	N020682	001	Dec 18, 1996	Feb	CAHN
AB	+		50MG	N020682	002	Dec 18, 1996	Feb	CAHN
AB	+		100MG	N020682	003	Dec 18, 1996	Feb	CAHN

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL

AMZEEQ

>D>	+!	FOAMIX	EQ 4% BASE	N212379	001	Oct 18, 2019	Mar	CAHN
>A>	+!	VYNE	EQ 4% BASE	N212379	001	Oct 18, 2019	Mar	CAHN
		ZILXI						
>D>	+!	FOAMIX	EQ 1.5% BASE	N213690	001	May 28, 2020	Mar	CAHN
>A>	+!	VYNE	EQ 1.5% BASE	N213690	001	May 28, 2020	Mar	CAHN

MINOXIDILTABLET; ORAL
LONITEN

+ @	PFIZER	2.5MG	N018154	001		Feb	CAHN
+ @		10MG	N018154	003		Feb	CAHN

>A> MIRABEGRON>A> FOR SUSPENSION, EXTENDED RELEASE; ORAL
>A> MYRBETRIQ GRANULES

>A>	+!	APGDI	8MG/ML	N213801	001	Mar 25, 2021	Mar	NEWA
-----	----	-------	--------	---------	-----	--------------	-----	------

MOMETASONE FUROATEOINTMENT; TOPICAL
MOMETASONE FUROATE

@	TORRENT	0.1%	A207899	001	Jul 13, 2018	Jan	DISC
---	---------	------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL
NASONEX

AB	+!	ORGANON	0.05MG/SPRAY	N020762	001	Oct 01, 1997	Feb	CAHN
----	----	---------	--------------	---------	-----	--------------	-----	------

MORPHINE SULFATESOLUTION; ORAL
MORPHINE SULFATE

@	ANI PHARMS INC	10MG/5ML	A205509	001	Apr 17, 2018	Jan	DISC
---	----------------	----------	---------	-----	--------------	-----	------

@		20MG/5ML	A205509	002	Apr 17, 2018	Jan	DISC
---	--	----------	---------	-----	--------------	-----	------

@		100MG/5ML	A205509	003	Apr 17, 2018	Jan	DISC
---	--	-----------	---------	-----	--------------	-----	------

AA		WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Feb	NEWA
----	--	-----------------	----------	---------	-----	--------------	-----	------

AA			20MG/5ML	A211454	002	Feb 12, 2021	Feb	NEWA
----	--	--	----------	---------	-----	--------------	-----	------

AA			100MG/5ML	A211454	003	Feb 12, 2021	Feb	NEWA
----	--	--	-----------	---------	-----	--------------	-----	------

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1		UPSHER SMITH LABS	EQ 0.5% BASE	A212616	001	Feb 10, 2021	Jan	NEWA
-----	--	-------------------	--------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL HYDROCHLORIDEINJECTABLE; INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		AMNEAL	500MG/VIAL	A211374	001	Mar 05, 2021	Feb	NEWA
----	--	--------	------------	---------	-----	--------------	-----	------

AP		MEITHEAL	500MG/VIAL	A212130	001	Jan 15, 2021	Jan	CAHN
----	--	----------	------------	---------	-----	--------------	-----	------

AP		NANJING KING-FRIEND	500MG/VIAL	A212130	001	Jan 15, 2021	Jan	NEWA
----	--	---------------------	------------	---------	-----	--------------	-----	------

MYCOPHENOLIC ACIDTABLET, DELAYED RELEASE; ORAL
MYCOPHENOLIC ACID

AB		AMTA	180MG	A214376	001	Feb 10, 2021	Jan	NEWA
----	--	------	-------	---------	-----	--------------	-----	------

AB			360MG	A214376	002	Feb 10, 2021	Jan	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

NABUMETONETABLET; ORAL
NABUMETONE

>A>	AB		ANNORA PHARMA	500MG	A090445	001	Jan 12, 2011	Mar	CAHN
-----	----	--	---------------	-------	---------	-----	--------------	-----	------

>A>	AB			500MG	A090445	001	Jan 12, 2011	Mar	CAHN
-----	----	--	--	-------	---------	-----	--------------	-----	------

>A>	AB			750MG	A090445	002	Jan 12, 2011	Mar	CAHN
-----	----	--	--	-------	---------	-----	--------------	-----	------

>A>	AB			750MG	A090445	002	Jan 12, 2011	Mar	CAHN
-----	----	--	--	-------	---------	-----	--------------	-----	------

>D>	AB		LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Mar	CAHN
-----	----	--	-----------	-------	---------	-----	--------------	-----	------

>D>	AB			750MG	A090445	002	Jan 12, 2011	Mar	CAHN
-----	----	--	--	-------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	1MG/ML	A213279	001	Jan 14, 2021	Jan	NEWA
----	--	----------------------	--------	---------	-----	--------------	-----	------

AP		BAXTER HLTHCARE CORP	0.4MG/ML	A214785	001	Jan 29, 2021	Jan	NEWA
----	--	----------------------	----------	---------	-----	--------------	-----	------

NAPROXENSUSPENSION; ORAL
NAPROXEN

AB		NOVITIUM PHARMA	25MG/ML	A211910	001	Mar 10, 2021	Feb	NEWA
----	--	-----------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL
NAPROXEN

AB		GRANULES	250MG	A074140	001	Dec 21, 1993	Feb	CMFD
----	--	----------	-------	---------	-----	--------------	-----	------

AB			375MG	A074140	002	Dec 21, 1993	Feb	CMFD
----	--	--	-------	---------	-----	--------------	-----	------

	TABLET;ORAL							
	NAPROXEN							
AB		500MG		A074140	003	Dec 21, 1993	Feb	CMFD
	<u>NEOSTIGMINE METHYLSULFATE</u>							
	SOLUTION;INTRAVENOUS							
	NEOSTIGMINE METHYLSULFATE							
>A>	AP	HONG KONG	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Mar	NEWA
>A>	AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Mar	NEWA
	<u>NICARDIPINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	NICARDIPINE HYDROCHLORIDE							
!	AM	REAGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Feb	CHRS
	<u>NISOLDIPINE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	NISOLDIPINE							
!	MYLAN		20MG	A079051	001	Jul 25, 2008	Jan	CHRS
			30MG	A079051	002	Jul 25, 2008	Jan	CHRS
	<u>NOREPINEPHRINE BITARTRATE</u>							
	INJECTABLE;INJECTION							
	NOREPINEPHRINE BITARTRATE							
>D>	AP	ANDERSEN GLOBAL	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Mar	CAHN
	AP		EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Jan	NEWA
>A>	AP	BRECKENRIDGE	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Mar	CAHN
	AP	SUN PHARM	EQ 1MG BASE/ML	A211980	001	Jan 29, 2021	Jan	NEWA
	SOLUTION;INTRAVENOUS							
	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE							
+	!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Jan	NEWA
+	!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Jan	NEWA
	<u>NORTRIPTYLINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	NORTRIPTYLINE HYDROCHLORIDE							
AB	ZYDUS		EQ 10MG BASE	A213441	001	Feb 24, 2021	Feb	NEWA
AB			EQ 25MG BASE	A213441	002	Feb 24, 2021	Feb	NEWA
AB			EQ 50MG BASE	A213441	003	Feb 24, 2021	Feb	NEWA
AB			EQ 75MG BASE	A213441	004	Feb 24, 2021	Feb	NEWA
	<u>NYSTATIN</u>							
	OINTMENT;TOPICAL							
	NYSTATIN							
AT	MACLEODS PHARMS LTD		100,000 UNITS/GM	A213826	001	Jan 14, 2021	Jan	NEWA
	<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>							
	CREAM;TOPICAL							
	NYSTATIN AND TRIAMCINOLONE ACETONIDE							
>A>	AT	ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214090	001	Mar 31, 2021	Mar	NEWA
	<u>OFLOXACIN</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	OFLOXACIN							
@	ALVOGEN		0.3%	A076830	001	Aug 31, 2004	Jan	DISC
	TABLET;ORAL							
	FLOXIN							
+	@	JANSSEN PHARMS	200MG	N019735	001	Dec 28, 1990	Jan	CRLD
+	@		300MG	N019735	002	Dec 28, 1990	Jan	CRLD
+	@		400MG	N019735	003	Dec 28, 1990	Jan	CRLD
	<u>OLANZAPINE</u>							
	TABLET;ORAL							
	OLANZAPINE							
AB	HISUN PHARM HANGZHOU		2.5MG	A206924	001	Dec 31, 2020	Feb	CAHN
AB			5MG	A206924	002	Dec 31, 2020	Feb	CAHN
AB			7.5MG	A206924	003	Dec 31, 2020	Feb	CAHN
AB			10MG	A206924	004	Dec 31, 2020	Feb	CAHN
AB			15MG	A206924	005	Dec 31, 2020	Feb	CAHN
AB			20MG	A206924	006	Dec 31, 2020	Feb	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB	HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020	Feb CAHN
AB		10MG	A206892	002	Dec 31, 2020	Feb CAHN
AB		15MG	A206892	003	Dec 31, 2020	Feb CAHN
AB		20MG	A206892	004	Dec 31, 2020	Feb CAHN

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>D>	AT	AKORN	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Mar CTEC
>A>			EQ 0.2% BASE	A204723	001	Dec 05, 2017	Mar CTEC
>D>		@ CIPLA	EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar CMKT

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

>D>		@ AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Mar CMFD
>A>	AB		0.665MG/SPRAY	A210901	001	Jan 28, 2020	Mar CMFD
		@	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
LOVAZA

AB	+!	WOODWARD	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb CAHN
----	----	----------	------------------------------------------------------------------------	---------	-----	--------------	----------

ONDANSETRON

FILM;ORAL
ZUPLENZ

	+	@ AQUESTIVE	4MG	N022524	001	Jul 02, 2010	Feb CAHN
	+	@	8MG	N022524	002	Jul 02, 2010	Feb CAHN

>A> ORITAVANCIN DIPHOSPHATE

>A>			POWDER; INTRAVENOUS				
>A>			KIMYRSA				
>A>	+!	MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021	Mar NEWA

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL
ORPHENADRINE CITRATE

		@ IMPAX PHARMS	100MG	A040368	001	Jun 23, 2000	Jan DISC
--	--	----------------	-------	---------	-----	--------------	----------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

		@ MYLAN	EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan DISC
AB			EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan NEWA
		@	EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan DISC
AB			EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan NEWA
		@	EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan DISC
AB			EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan NEWA

OXYBUTYNIN CHLORIDE

TABLET;ORAL
OXYBUTYNIN CHLORIDE

AB		APPCO	5MG	A209025	001	Dec 21, 2017	Jan CAHN
----	--	-------	-----	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

TABLET;ORAL
OXAYDO

>D>		ZYLA	5MG	N202080	001	Jun 17, 2011	Mar CRLD
>A>	+		5MG	N202080	001	Jun 17, 2011	Mar CRLD
>D>			7.5MG	N202080	002	Jun 17, 2011	Mar CRLD
>A>	+		7.5MG	N202080	002	Jun 17, 2011	Mar CRLD

PACLITAXEL

INJECTABLE; INJECTION
PACLITAXEL

>D>	AP	MYLAN LABS LTD	6MG/ML	A091540	001	Sep 29, 2011	Mar DISC
>A>		@	6MG/ML	A091540	001	Sep 29, 2011	Mar DISC

PALONOSETRON HYDROCHLORIDEINJECTABLE; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

>A>	AP	ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Mar	NEWA
-----	----	-----------------	----------------------------------------	---------	-----	--------------	-----	------

PAROXETINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

AB		CSPC OUYI	EQ 12.5MG BASE	A213485	001	Feb 16, 2021	Feb	NEWA
AB			EQ 25MG BASE	A213485	002	Feb 16, 2021	Feb	NEWA
AB			EQ 37.5MG BASE	A213485	003	Feb 16, 2021	Feb	NEWA

PEMETREXEDSOLUTION; INTRAVENOUS
PEMETREXED

		+ @ ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	Jan	DISC
		+ @	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	Jan	DISC
		+ @	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	Jan	DISC

PENICILLIN G POTASSIUMINJECTABLE; INJECTION
PENICILLIN G POTASSIUM

>D>		HANFORD GC	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009	Mar	CAHN
>D>	AP		5,000,000 UNITS/VIAL	A065149	002	Jul 23, 2009	Mar	CAHN
>D>	AP		20,000,000 UNITS/VIAL	A065149	003	Jul 23, 2009	Mar	CAHN
>A>		HQ SPECLT PHARMA	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009	Mar	CAHN
>A>	AP		5,000,000 UNITS/VIAL	A065149	002	Jul 23, 2009	Mar	CAHN
>A>	AP		20,000,000 UNITS/VIAL	A065149	003	Jul 23, 2009	Mar	CAHN

PENICILLIN V POTASSIUMFOR SOLUTION; ORAL
PENICILLIN V POTASSIUM

>D>		DAVA PHARMS INC	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Mar	DISC
>A>		@	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Mar	DISC
>D>	AA		EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Mar	DISC
>A>		@	EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Mar	DISC
		PENICILLIN-VK						
>D>	AA	TEVA	EQ 125MG BASE/5ML	A060456	001		Mar	CTEC
>A>			EQ 125MG BASE/5ML	A060456	001		Mar	CTEC
>D>	AA	!	EQ 250MG BASE/5ML	A060456	002		Mar	CTEC
>A>		!	EQ 250MG BASE/5ML	A060456	002		Mar	CTEC

PENTAMIDINE ISETHIONATEINJECTABLE; INJECTION
PENTAMIDINE ISETHIONATE

AP		EMCURE PHARMS LTD	300MG/VIAL	A213806	001	Jan 07, 2021	Jan	NEWA
----	--	-------------------	------------	---------	-----	--------------	-----	------

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
TRENTAL

		+ @ VALIDUS PHARMS	400MG	N018631	001	Aug 30, 1984	Feb	CAHN
--	--	--------------------	-------	---------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS
BIORPHEN

>A>		+! ETON PHARMS	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb	CPOT
		+!	10MG/10ML (10MG/ML)	N212909	002	Mar 11, 2021	Mar	NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2		AUROBINDO PHARMA LTD	10MG/ML (10MG/ML)	A210696	001	Jan 07, 2021	Jan	NEWA
AP2	+	HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Jan	CAHN
AP2	+		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jan	CAHN
AP2	+		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jan	CAHN
AP1		PROVEPHARM SAS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jan	CAHN
AP1			50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jan	CAHN
AP1			100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jan	CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE						
AA	AKORN	5MG/5ML; 6.25MG/5ML	A040675	001	Dec 23, 2014	Feb	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

	PIOGLITAZONE HYDROCHLORIDE						
AB	ANNORA PHARMA	EQ 15MG BASE	A204133	001	Apr 07, 2014	Jan	CAHN
AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Jan	CAHN
AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Jan	CAHN
AB	SHUANGCHENG	EQ 15MG BASE	A210165	001	Jan 22, 2021	Jan	NEWA
AB		EQ 30MG BASE	A210165	002	Jan 22, 2021	Jan	NEWA
AB		EQ 45MG BASE	A210165	003	Jan 22, 2021	Jan	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	AP	MYLAN LABS LTD	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Mar	DISC
>A>		@	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Mar	DISC
	AP	PROVEPHARM SAS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan	CAHN
	AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan	CAHN
	AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan	CAHN
	AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan	CAHN
	AP		EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Jan	CAHN
	AP	SAGENT PHARMS INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A208674	001	Feb 16, 2021	Feb	NEWA
	AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A208674	002	Feb 16, 2021	Feb	NEWA
	AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A208674	003	Feb 16, 2021	Feb	NEWA
	AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A208675	001	Feb 16, 2021	Feb	NEWA
	AP	! WOCKHARDT BIO AG	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Jan	CHRS
	AP	!	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Jan	CHRS
	AP	!	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Jan	CHRS
	AP	!	EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan	CHRS
		ZOSYN						
	+	@ WYETH PHARMS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Jan	DISC
	+	@	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Jan	DISC
	+	@	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Jan	DISC
	+	@	EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Jan	DISC

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	NOSTRUM LABS INC	10MG	A074118	002	Jun 15, 1993	Jan	CMS1
----	------------------	------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

	@ BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Feb	DISC
	@	2MG	A210111	002	Oct 30, 2020	Feb	DISC
	@	3MG	A210111	003	Oct 30, 2020	Feb	DISC
	@	4MG	A210111	004	Oct 30, 2020	Feb	DISC

>A>	<u>PONESIMOD</u>									
>A>	TABLET;ORAL									
>A>	PONVORY									
>A>	+	JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021	Mar	NEWA		
>A>	+		3MG	N213498	002	Mar 18, 2021	Mar	NEWA		
>A>	+		4MG	N213498	003	Mar 18, 2021	Mar	NEWA		
>A>	+		5MG	N213498	004	Mar 18, 2021	Mar	NEWA		
>A>	+		6MG	N213498	005	Mar 18, 2021	Mar	NEWA		
>A>	+		7MG	N213498	006	Mar 18, 2021	Mar	NEWA		
>A>	+		8MG	N213498	007	Mar 18, 2021	Mar	NEWA		
>A>	+		9MG	N213498	008	Mar 18, 2021	Mar	NEWA		
>A>	+		10MG	N213498	009	Mar 18, 2021	Mar	NEWA		
>A>	+		20MG	N213498	010	Mar 18, 2021	Mar	NEWA		
	<u>POSACONAZOLE</u>									
	TABLET, DELAYED RELEASE;ORAL									
	POSACONAZOLE									
AB		AET PHARMA	100MG	A213454	001	Feb 01, 2021	Jan	NEWA		
	<u>POTASSIUM CHLORIDE</u>									
	CAPSULE, EXTENDED RELEASE;ORAL									
	POTASSIUM CHLORIDE									
AB		GRANULES	8MEQ	A214686	001	Feb 16, 2021	Feb	NEWA		
AB			10MEQ	A214686	002	Feb 16, 2021	Feb	NEWA		
	FOR SOLUTION;ORAL									
	POTASSIUM CHLORIDE									
>A>	AA	STRIDES PHARMA	20MEQ	A211667	001	Mar 11, 2021	Mar	NEWA		
	INJECTABLE;INJECTION									
	POTASSIUM CHLORIDE 10MEQ									
>D>	AP	FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar	DISC		
>A>	@		14.9MG/ML	A211087	001	Sep 09, 2020	Mar	DISC		
>D>	AP		746MG/100ML	A211087	002	Sep 09, 2020	Mar	DISC		
>A>	@		746MG/100ML	A211087	002	Sep 09, 2020	Mar	DISC		
>A>	AP	NEXUS PHARMS	14.9MG/ML	A214727	001	Mar 18, 2021	Mar	NFTG		
>A>	AP		745MG/100ML	A214727	002	Mar 18, 2021	Mar	NFTG		
	POTASSIUM CHLORIDE 20MEQ									
>D>	AP	FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar	DISC		
>A>	@		29.8MG/ML	A211087	003	Sep 09, 2020	Mar	DISC		
>A>	AP	NEXUS PHARMS	29.8MG/ML	A214727	003	Mar 18, 2021	Mar	NFTG		
>A>	AP		1.49GM/100ML	A214727	004	Mar 18, 2021	Mar	NFTG		
	POTASSIUM CHLORIDE 40MEQ									
>D>	AP	FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar	DISC		
>A>	@		2.98GM/100ML	A211087	004	Sep 09, 2020	Mar	DISC		
>A>	AP	NEXUS PHARMS	2.98GM/100ML	A214727	005	Mar 18, 2021	Mar	NFTG		
	SOLUTION;ORAL									
	POTASSIUM CHLORIDE									
AA		GRANULES PHARMS	20MEQ/15ML	A213392	001	Jan 29, 2021	Jan	NEWA		
AA			40MEQ/15ML	A213392	002	Jan 29, 2021	Jan	NEWA		
	TABLET, EXTENDED RELEASE;ORAL									
	POTASSIUM CHLORIDE									
AB1		AMTA	10MEQ	A214395	001	Jan 28, 2021	Jan	NEWA		
AB1			20MEQ	A214395	002	Jan 28, 2021	Jan	NEWA		
>A>	AB1	AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021	Mar	NEWA		
>A>	AB1		15MEQ	A214728	002	Mar 31, 2021	Mar	NEWA		
>A>	AB1		20MEQ	A214728	003	Mar 31, 2021	Mar	NEWA		
>D>	AB1	CENTAUR PHARMS PVT	10MEQ	A213588	001	Aug 21, 2020	Mar	DISC		
>A>	@		10MEQ	A213588	001	Aug 21, 2020	Mar	DISC		
>D>	AB1		20MEQ	A213588	002	Aug 21, 2020	Mar	DISC		
>A>	@		20MEQ	A213588	002	Aug 21, 2020	Mar	DISC		
	<u>POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>									
	INJECTABLE;INJECTION									
>A>	POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%									
>A>	+	BAXTER HLTHCARE	150MG/100ML;450MG/100ML	N017648	005	Nov 26, 2002	Mar	CTNA		
>D>	AP	FRESENIUS KABI USA	150MG/100ML;450MG/100ML	A212347	001	Sep 17, 2020	Mar	DISC		
>A>	@		150MG/100ML;450MG/100ML	A212347	001	Sep 17, 2020	Mar	DISC		
>D>	POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
>D>	AP	+	BAXTER HLTHCARE	150MG/100ML;450MG/100ML	N017648	005	Nov 26, 2002	Mar	CTNA	
>A>	POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%									
>A>	AP	+	BAXTER HLTHCARE	150MG/100ML;900MG/100ML	N017648	001		Mar	CTNA	

INJECTABLE; INJECTION

>D>		POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	+ BAXTER HLTHCARE	150MG/100ML;900MG/100ML	N017648	001		Mar CTNA
>A>		POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%					
>A>		+! BAXTER HLTHCARE	300MG/100ML;900MG/100ML	N017648	002		Mar CTNA
>D>	AP	FRESENIUS KABI USA	300MG/100ML;900MG/100ML	A212347	002	Sep 17, 2020	Mar DISC
>A>		@	300MG/100ML;900MG/100ML	A212347	002	Sep 17, 2020	Mar DISC
>D>		POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	+ BAXTER HLTHCARE	300MG/100ML;900MG/100ML	N017648	002		Mar CTNA
>A>		SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%					
>A>		@ BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004		Mar CTNA
>D>		SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER					
>D>		@ BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004		Mar CTNA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB		ASCENT PHARMS INC	5MEQ	A214420	001	Feb 05, 2021	Jan NEWA
AB			10MEQ	A214420	002	Feb 05, 2021	Jan NEWA
AB			15MEQ	A214420	003	Feb 05, 2021	Jan NEWA
		@ BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Feb DISC
		@	15MEQ	A212799	002	Jun 29, 2020	Feb DISC
AB		EYWA	5MEQ	A214426	001	Feb 19, 2021	Feb NEWA
AB			10MEQ	A214426	002	Feb 19, 2021	Feb NEWA
AB			15MEQ	A214426	003	Feb 19, 2021	Feb NEWA

PRALSETINIB

CAPSULE; ORAL

GAVRETO

>D>		+! BLUEPRINT MEDICINES	100MG	N213721	001	Sep 04, 2020	Mar CAHN
>A>		+! GENENTECH INC	100MG	N213721	001	Sep 04, 2020	Mar CAHN

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

@ DR REDDYS LABS LTD EQ 5MG BASE
 @ EQ 10MG BASE

A205926	001	Jul 07, 2020	Jan DISC
A205926	002	Jul 07, 2020	Jan DISC

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB		BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan CAHN
AB			20MG	A209869	002	Apr 13, 2018	Jan CAHN
AB			40MG	A209869	003	Apr 13, 2018	Jan CAHN
AB			80MG	A209869	004	Apr 13, 2018	Jan CAHN
		@ HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan DISC
		@	40MG	A206061	002	Nov 23, 2018	Jan DISC
		@	80MG	A206061	003	Nov 23, 2018	Jan DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AB		ANI PHARMS INC	EQ 1MG BASE	A072577	002	May 16, 1989	Feb CMFD
AB			EQ 2MG BASE	A072577	001	May 16, 1989	Feb CMFD
AB			EQ 5MG BASE	A072577	003	May 16, 1989	Feb CMFD

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

>D>		@ CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Mar CMFD
>A>	AA		15MG/5ML	A040323	001	May 13, 1999	Mar CMFD

TABLET; ORAL

PREDNISOLONE

@ RISING 5MG

A084773	001		Jan CAHN
---------	-----	--	----------

PREDNISONE

TABLET; ORAL

PREDNISONE

		@ RISING	10MG	A089983	001	Jan 12, 1989	Jan CAHN
		@	20MG	A085813	001		Jan CAHN
		@	50MG	A089984	001	Jan 12, 1989	Jan CAHN
AB		STRIDES PHARMA	10MG	A208412	001	Feb 11, 2021	Feb NEWA

	TABLET;ORAL							
	PREDNISONE							
AB		20MG	A208412	002	Feb 11, 2021	Feb	NEWA	
	<u>PREGABALIN</u>							
	CAPSULE;ORAL							
	PREGABALIN							
AB	ALKEM LABS LTD	25MG	A207799	007	Sep 30, 2019	Feb	CMS1	
AB		50MG	A207799	008	Sep 30, 2019	Feb	CMS1	
	<u>PROMETHAZINE HYDROCHLORIDE</u>							
	SYRUP;ORAL							
	PROMETHAZINE HYDROCHLORIDE							
	@ AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Feb	DISC	
	<u>PROPYLTHIOURACIL</u>							
	TABLET;ORAL							
	PROPYLTHIOURACIL							
>D>	@ QUAGEN	50MG	A080154	001		Mar	CMFD	
>A>	BD	50MG	A080154	001		Mar	CMFD	
	<u>QUETIAPINE FUMARATE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	QUETIAPINE FUMARATE							
	@ MYLAN	EQ 50MG BASE	A202228	001	Feb 02, 2021	Feb	DISC	
AB		EQ 50MG BASE	A202228	001	Feb 02, 2021	Jan	NEWA	
	@	EQ 150MG BASE	A202228	002	Feb 02, 2021	Feb	DISC	
AB		EQ 150MG BASE	A202228	002	Feb 02, 2021	Jan	NEWA	
	@	EQ 200MG BASE	A202228	003	Feb 02, 2021	Feb	DISC	
AB		EQ 200MG BASE	A202228	003	Feb 02, 2021	Jan	NEWA	
	@	EQ 300MG BASE	A202228	004	Feb 02, 2021	Feb	DISC	
AB		EQ 300MG BASE	A202228	004	Feb 02, 2021	Jan	NEWA	
	@	EQ 400MG BASE	A202228	005	Feb 02, 2021	Feb	DISC	
AB		EQ 400MG BASE	A202228	005	Feb 02, 2021	Jan	NEWA	
	<u>QUINIDINE GLUCONATE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	QUINIDINE GLUCONATE							
	@ RISING	324MG	A089894	001	Dec 15, 1988	Jan	CAHN	
	<u>RANITIDINE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	RANITIDINE HYDROCHLORIDE							
	@ WOCKHARDT LTD	EQ 150MG BASE	A075208	001	Dec 17, 1998	Jan	DISC	
	@	EQ 300MG BASE	A075208	002	Dec 17, 1998	Jan	DISC	
	<u>RANOLAZINE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	RANOLAZINE							
>A>	AB	AMNEAL	500MG	A207690	001	Mar 11, 2021	Mar	NEWA
>A>	AB		1GM	A207690	002	Mar 11, 2021	Mar	NEWA
AB	GRAVITI PHARMS	500MG	A212889	001	Jan 28, 2021	Jan	NEWA	
AB		1GM	A212889	002	Jan 28, 2021	Jan	NEWA	
AB	PRAXGEN	500MG	A212781	001	Mar 23, 2020	Feb	CAHN	
AB		1GM	A212781	002	Mar 23, 2020	Feb	CAHN	
	<u>RIFAMPIN</u>							
	INJECTABLE;INJECTION							
	RIFAMPIN							
	@ WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016	Feb	DISC	
	<u>RILUZOLE</u>							
	FILM;ORAL							
	EXSERVAN							
	+!	! MITSUBISHI HOLDINGS	50MG	N212640	001	Nov 22, 2019	Feb	CAHN
	<u>RISPERIDONE</u>							
	TABLET, ORALLY DISINTEGRATING;ORAL							
	RISPERDAL							
	+ @	JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003	Feb	DISC
	+ @		1MG	N021444	002	Apr 02, 2003	Feb	DISC
	+ @		2MG	N021444	003	Apr 02, 2003	Feb	DISC

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERDAL

	+ @	3MG	N021444	004	Dec 23, 2004	Feb	DISC
	+ @	4MG	N021444	005	Dec 23, 2004	Feb	DISC
		RISPERIDONE					
AB	!	JUBILANT GENERICS	1MG	A090839	002	Nov 04, 2011	Feb CHRS

RITONAVIR

>D>		CAPSULE;ORAL					
>D>		RITONAVIR					
>D>	!	HIKMA	100MG	A205801	001	Dec 03, 2020	Mar DISC
>A>	@		100MG	A205801	001	Dec 03, 2020	Mar DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

>D>	@	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	Mar CRLD
>A>	+ @		50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	Mar CRLD
>D>	@		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Mar CRLD
>A>	+ @		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Mar CRLD
		ROPIVACAINE HYDROCHLORIDE					
	@	MYLAN ASI	150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Jan DISC
	@		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Jan DISC

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB		INVENTIA	5MG	A207653	001	Feb 05, 2021	Jan NEWA
AB			10MG	A207653	002	Feb 05, 2021	Jan NEWA
AB			20MG	A207653	003	Feb 05, 2021	Jan NEWA
AB			40MG	A207653	004	Feb 05, 2021	Jan NEWA
AB		ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Feb CMFD
AB			10MG	A212059	002	Nov 04, 2019	Feb CMFD
AB			20MG	A212059	003	Nov 04, 2019	Feb CMFD
AB			40MG	A212059	004	Nov 04, 2019	Feb CMFD

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

AB		ALKEM LABS LTD	40MG/ML	A213410	001	Feb 23, 2021	Feb NEWA
----	--	----------------	---------	---------	-----	--------------	----------

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

SAPROPTERIN DIHYDROCHLORIDE

>A>	AB	DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Mar NEWA
-----	----	-----------	--------------	---------	-----	--------------	----------

SCOPOLAMINE

SYSTEM;TRANSDERMAL

TRANSDERM SCOP

>A>	AB	+!	BAXTER HLTHCARE CORP	1MG/72HR	N017874	001	Mar CAHN
>D>	AB	+!	GLAXOSMITHKLINE CON	1MG/72HR	N017874	001	Mar CAHN

SELENIOS ACID

SOLUTION;INTRAVENOUS

SELENIOS ACID

	+!	AM REGENT	EQ 60MCG BASE/ML (EQ 60MCG BASE/ML)	N209379	002	Jan 25, 2021	Jan NEWA
--	----	-----------	-------------------------------------	---------	-----	--------------	----------

SELEXIPAG

TABLET;ORAL

UPTRAVI

	+	ACTELION	0.2MG	N207947	001	Dec 21, 2015	Feb CAHN
	+!		0.4MG	N207947	002	Dec 21, 2015	Feb CAHN
	+		0.6MG	N207947	003	Dec 21, 2015	Feb CAHN
	+		0.8MG	N207947	004	Dec 21, 2015	Feb CAHN
	+		1MG	N207947	005	Dec 21, 2015	Feb CAHN
	+		1.2MG	N207947	006	Dec 21, 2015	Feb CAHN
	+		1.4MG	N207947	007	Dec 21, 2015	Feb CAHN
	+		1.6MG	N207947	008	Dec 21, 2015	Feb CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jan	CMFD
AB		EQ 50MG BASE	A076881	002	Feb 06, 2007	Jan	CMFD
AB		EQ 100MG BASE	A076881	003	Feb 06, 2007	Jan	CMFD

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

>D>	AB	IMPAX	800MG/PACKET	A211316	001	Nov 20, 2020	Mar	DISC
>A>		@	800MG/PACKET	A211316	001	Nov 20, 2020	Mar	DISC
>D>	AB		2.4GM/PACKET	A211316	002	Nov 20, 2020	Mar	DISC
>A>		@	2.4GM/PACKET	A211316	002	Nov 20, 2020	Mar	DISC

TABLET;ORAL

SEVELAMER CARBONATE

>D>		@ ANXIN	800MG	A212970	001	Apr 09, 2020	Mar	CMFD
>A>	AB		800MG	A212970	001	Apr 09, 2020	Mar	CMFD
	AB	LUPIN LTD	800MG	A204600	001	Jan 14, 2021	Jan	NEWA

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

>D>	AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Mar	CAHN
>A>	AB		EQ 25MG BASE	A208494	001	Jun 12, 2020	Mar	CAHN
>D>	AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Mar	CAHN
>A>	AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Mar	CAHN
>D>	AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Mar	CAHN
>A>	AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Mar	CAHN

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

>D>	AB	BIOCON LIMITED	5MG	A078034	001	Dec 20, 2006	Mar	CAHN
>D>	AB		10MG	A078034	002	Dec 20, 2006	Mar	CAHN
>D>	AB		20MG	A078034	003	Dec 20, 2006	Mar	CAHN
>D>	AB		40MG	A078034	004	Dec 20, 2006	Mar	CAHN
>D>	AB		80MG	A078034	005	Dec 20, 2006	Mar	CAHN
>A>	AB	BIOCON PHARMA	5MG	A078034	001	Dec 20, 2006	Mar	CAHN
>A>	AB		10MG	A078034	002	Dec 20, 2006	Mar	CAHN
>A>	AB		20MG	A078034	003	Dec 20, 2006	Mar	CAHN
>A>	AB		40MG	A078034	004	Dec 20, 2006	Mar	CAHN
>A>	AB		80MG	A078034	005	Dec 20, 2006	Mar	CAHN
		ZOCOR						
	AB	+ ORGANON	5MG	N019766	001	Dec 23, 1991	Feb	CAHN
	AB	+	10MG	N019766	002	Dec 23, 1991	Feb	CAHN
	AB	+	20MG	N019766	003	Dec 23, 1991	Feb	CAHN
	AB	+	40MG	N019766	004	Dec 23, 1991	Feb	CAHN
	AB	+	80MG	N019766	005	Jul 10, 1998	Feb	CAHN

SIROLIMUS

TABLET;ORAL

SIROLIMUS

>A>	AB	ALKEM LABS LTD	0.5MG	A214753	001	Mar 12, 2021	Mar	NEWA
>A>	AB		1MG	A214753	002	Mar 12, 2021	Mar	NEWA
>A>	AB		2MG	A214753	003	Mar 12, 2021	Mar	NEWA

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP	NUKEMED	10-200mCi/ML	A203912	001	Apr 22, 2015	Jan	CAHN
----	---------	--------------	---------	-----	--------------	-----	------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB	NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jan	CMFD
	OSMOPREP						
AB	+! SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Jan	CTEC

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL
KIONEX

>A>	AA	ANI PHARMS INC	454GM/BOT	A 040029	001	Feb 06, 1998	Mar CAHN
>D>	AA	PADDOCK LLC	454GM/BOT	A 040029	001	Feb 06, 1998	Mar CAHN

SUSPENSION;ORAL, RECTAL
KIONEX

>A>		@ ANI PHARMS INC	15GM/60ML	A 040028	001	Sep 17, 2007	Mar CAHN
>D>		@ PADDOCK LLC	15GM/60ML	A 040028	001	Sep 17, 2007	Mar CAHN
>A>		@ ANI PHARMS INC	15GM/60ML	A 090590	001	May 13, 2011	Mar CAHN
>D>		@ PADDOCK LLC	15GM/60ML	A 090590	001	May 13, 2011	Mar CAHN

SOLIFENACIN SUCCINATETABLET;ORAL
SOLIFENACIN SUCCINATE

>D>	AB	ZYDUS PHARMS	5MG	A 207721	001	Oct 19, 2020	Mar DISC
>A>		@	5MG	A 207721	001	Oct 19, 2020	Mar DISC
>D>	AB		10MG	A 207721	002	Oct 19, 2020	Mar DISC
>A>		@	10MG	A 207721	002	Oct 19, 2020	Mar DISC

SOTALOL HYDROCHLORIDETABLET;ORAL
SOTALOL HYDROCHLORIDE

		@ MYLAN	80MG	A 077616	001	Feb 07, 2007	Feb DISC
		@	120MG	A 077616	002	Feb 07, 2007	Feb DISC
		@	160MG	A 077616	003	Feb 07, 2007	Feb DISC

STERILE WATER FOR INJECTIONLIQUID;N/A
STERILE WATER FOR INJECTION

!	NEPHRON	100% (5ML)	A 211222	001	Feb 10, 2021	Jan NEWA
---	---------	------------	----------	-----	--------------	----------

SUCCINYLCHOLINE CHLORIDEINJECTABLE;INJECTION
SUCCINYLCHOLINE CHLORIDE

>D>		@ ACCORD HLTHCARE	20MG/ML	A 213705	001	May 20, 2020	Mar CMFD
>A>	AP		20MG/ML	A 213705	001	May 20, 2020	Mar CMFD
>A>		@ HIKMA	20MG/ML	A 213229	001	Jun 12, 2020	Feb DISC
>A>	AP	SAGENT PHARMS INC	20MG/ML	A 215022	001	Mar 29, 2021	Mar NEWA

SULFAMETHOXAZOLETABLET;ORAL
SULFAMETHOXAZOLE

		@ RISING	500MG	A 085844	001		Jan CAHN
--	--	----------	-------	----------	-----	--	----------

SULFASALAZINETABLET;ORAL
AZULFIDINE

>A>	AB	+! PFIZER	500MG	N 007073	001		Mar CAHN
>D>	AB	+! PHARMACIA AND UPJOHN	500MG	N 007073	001		Mar CAHN

TABLET, DELAYED RELEASE;ORAL
AZULFIDINE EN-TABS

>A>	AB	+! PFIZER	500MG	N 007073	002	Apr 06, 1983	Mar CAHN
>D>	AB	+! PHARMACIA AND UPJOHN	500MG	N 007073	002	Apr 06, 1983	Mar CAHN

SULFISOXAZOLETABLET;ORAL
SULFISOXAZOLE

		@ RISING	500MG	A 085628	001		Jan CAHN
--	--	----------	-------	----------	-----	--	----------

SUMATRIPTANSPRAY;NASAL
SUMATRIPTAN

	AB	CIPLA	20MG/SPRAY	A 214209	001	Feb 22, 2021	Feb NEWA
>A>	AB	FLORIDA	20MG/SPRAY	A 208967	001	Feb 17, 2021	Mar CAHN
>D>	AB	PHARMASERVE NW	20MG/SPRAY	A 208967	001	Feb 17, 2021	Mar CAHN
	AB		20MG/SPRAY	A 208967	001	Feb 17, 2021	Feb NEWA

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

@ MYLAN ASI

EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML)

A090641 001 Jul 28, 2010 Jan DISC

SPRAY;NASAL
SUMATRIPTAN

AB1 PERRIGO UK FINCO

5MG/SPRAY

A213465 002 Sep 21, 2020 Feb CMS1

TADALAFILTABLET;ORAL
CIALIS

AB1 + LILLY

2.5MG

N021368 004 Jan 07, 2008 Feb CTEC

AB1 +

5MG

N021368 001 Nov 21, 2003 Feb CTEC

AB1 +

10MG

N021368 002 Nov 21, 2003 Feb CTEC

TADALAFIL

AB1 ACCORD HLTHCARE

2.5MG

A209167 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209167 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209167 003 Oct 23, 2019 Feb CTEC

AB1 AJANTA PHARMA LTD

2.5MG

A209654 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209654 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209654 003 Mar 26, 2019 Feb CTEC

AB1 ALEMBIC PHARMS LTD

2.5MG

A204809 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A204809 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A204809 003 Mar 26, 2019 Feb CTEC

AB1 AMNEAL PHARMS CO

2.5MG

A209744 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209744 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209744 003 Mar 26, 2019 Feb CTEC

AB1 AUROBINDO PHARMA LTD

2.5MG

A206285 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A206285 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A206285 003 Mar 26, 2019 Feb CTEC

AB1 CIPLA

2.5MG

A209539 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209539 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209539 003 Mar 26, 2019 Feb CTEC

AB1 DR REDDYS LABS LTD

2.5MG

A210069 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A210069 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A210069 003 Mar 26, 2019 Feb CTEC

@ GLENMARK PHARMS LTD

2.5MG

A210716 001 Dec 29, 2020 Feb DISC

@

5MG

A210716 002 Dec 29, 2020 Feb DISC

@

10MG

A210716 003 Dec 29, 2020 Feb DISC

@

20MG

A210716 004 Dec 29, 2020 Feb DISC

AB1 HETERO LABS LTD III

2.5MG

A209908 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209908 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209908 003 Mar 26, 2019 Feb CTEC

AB1 LUPIN LTD

2.5MG

A210567 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A210567 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A210567 003 Mar 26, 2019 Feb CTEC

AB1 MACLEODS PHARMS LTD

2.5MG

A207244 001 Oct 07, 2019 Feb CTEC

AB1

5MG

A207244 002 Oct 07, 2019 Feb CTEC

AB1

10MG

A207244 003 Oct 07, 2019 Feb CTEC

AB1 MYLAN

2.5MG

A206956 001 Apr 29, 2019 Feb CTEC

AB1

5MG

A206957 001 Apr 29, 2019 Feb CTEC

AB1

10MG

A206956 002 Apr 29, 2019 Feb CTEC

AB1 QILU

2.5MG

A210420 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A210420 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A210420 003 Mar 26, 2019 Feb CTEC

AB1 SUN PHARM

2.5MG

A208934 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A208934 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A208934 003 Mar 26, 2019 Feb CTEC

AB1 SUNSHINE

2.5MG

A211335 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A211335 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A211335 003 Mar 26, 2019 Feb CTEC

AB1 TEVA PHARMS USA

2.5MG

A090141 001 May 22, 2018 Feb CTEC

AB1

5MG

A090141 002 May 22, 2018 Feb CTEC

AB1

10MG

A090141 003 May 22, 2018 Feb CTEC

AB1 TORRENT

2.5MG

A211839 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A211839 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A211839 003 Mar 26, 2019 Feb CTEC

AB1 UMEDICA LABS PVT LTD

2.5MG

A211298 001 Oct 23, 2020 Feb CTEC

AB1

5MG

A211298 002 Oct 23, 2020 Feb CTEC

AB1

10MG

A211298 003 Oct 23, 2020 Feb CTEC

AB1 UNICHEM

2.5MG

A209250 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209250 002 Mar 26, 2019 Feb CTEC

TABLET;ORALTADALAFIL

AB1		10MG	A209250	003	Mar 26, 2019	Feb CTEC
AB1	YANGLING BUCHANG	2.5MG	A208824	001	Oct 27, 2020	Feb CTEC
AB1		5MG	A208824	002	Oct 27, 2020	Feb CTEC
AB1		10MG	A208824	003	Oct 27, 2020	Feb CTEC
AB1	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A206693	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A206693	003	Mar 26, 2019	Feb CTEC

TAVABOROLESOLUTION;TOPICALTAVABOROLE

AB	CIPLA	5%	A212224	001	Feb 09, 2021	Jan NEWA
AB	FLATWING	5%	A211963	001	Feb 03, 2021	Feb CPOT
AB		5.0%	A211963	001	Feb 03, 2021	Jan NEWA
AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Feb CAHN
AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan NEWA

TELMISARTANTABLET;ORALTELMISARTAN

AB	CELLTRION	20MG	A078710	001	Jan 08, 2014	Feb CMFD
AB		40MG	A078710	002	Jan 08, 2014	Feb CMFD
AB		80MG	A078710	003	Jan 08, 2014	Feb CMFD

TEMOZOLOMIDECAPSULE;ORALTEMOZOLOMIDE

@	HERITAGE	5MG	A078879	001	Mar 01, 2010	Feb CAHN
@		20MG	A078879	002	Mar 01, 2010	Feb CAHN
@		100MG	A078879	003	Mar 01, 2010	Feb CAHN
@		140MG	A078879	005	Mar 01, 2010	Feb CAHN
@		180MG	A078879	006	Mar 01, 2010	Feb CAHN
@		250MG	A078879	004	Mar 01, 2010	Feb CAHN
@	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Jan DISC
@		20MG	A203959	002	Apr 18, 2017	Jan DISC
@		100MG	A203959	003	Apr 18, 2017	Jan DISC
@		140MG	A203959	004	Apr 18, 2017	Jan DISC
@		250MG	A203959	005	Apr 18, 2017	Jan DISC

TEPOTINIB HYDROCHLORIDETABLET;ORALTEPMETKO

+!	EMD SERONO INC	EQ 225MG BASE	N214096	001	Feb 03, 2021	Feb NEWA
----	----------------	---------------	---------	-----	--------------	----------

TERIFLUNOMIDETABLET;ORALTERIFLUNOMIDE

@	IMPAX	14MG	A209677	001	Jun 17, 2020	Feb DISC
---	-------	------	---------	-----	--------------	----------

TESTOSTERONEGEL;TRANSDERMALTESTOSTERONE

AB2	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A204570	002	Jul 17, 2020	Feb NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A204570	003	Jul 17, 2020	Feb NEWA

GEL, METERED;TRANSDERMALTESTOSTERONE

AB	ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Feb NEWA
----	----------------------	----------------------------------	---------	-----	--------------	----------

SOLUTION, METERED;TRANSDERMALTESTOSTERONE

AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan NEWA
----	----------	----------------------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATEINJECTABLE;INJECTIONDEPO-TESTOSTERONE

>A>	@	PFIZER	50MG/ML	A085635	001	Mar CAHN
>A>	AO	!	100MG/ML	A085635	002	Mar CAHN
>A>	AO	!	200MG/ML	A085635	003	Mar CAHN
>D>	@	PHARMACIA AND UPJOHN	50MG/ML	A085635	001	Mar CAHN
>D>	AO	!	100MG/ML	A085635	002	Mar CAHN
>D>	AO	!	200MG/ML	A085635	003	Mar CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

	MYLAN	10MG	A 088004	002	Mar 15, 1983	Jan	CTEC
		25MG	A 088004	003	Mar 15, 1983	Jan	CTEC
		50MG	A 088004	004	Mar 15, 1983	Jan	CTEC
!		100MG	A 088004	001	Nov 18, 1983	Jan	CTEC
@	SUN PHARM INDUSTRIES	10MG	A 089953	004	Aug 01, 1986	Jan	DISC
@		25MG	A 089953	003	Aug 01, 1986	Jan	DISC
@		50MG	A 089953	002	Aug 01, 1986	Jan	DISC
@		100MG	A 089953	001	Oct 07, 1988	Jan	DISC

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

THIOTEPA

AP	GLAND PHARMA LTD	15MG/VIAL	A 214222	001	Mar 08, 2021	Feb	NEWA
----	------------------	-----------	----------	-----	--------------	-----	------

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

TIAGABINE HYDROCHLORIDE

@	WILSHIRE PHARMS INC	2MG	A 206857	001	Oct 13, 2017	Jan	DISC
@		4MG	A 206857	002	Oct 13, 2017	Jan	DISC
@		12MG	A 206857	003	Oct 13, 2017	Jan	DISC
@		16MG	A 206857	004	Oct 13, 2017	Jan	DISC

TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

>D>	+	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N 021936	002	Sep 15, 2015	Mar	CHRS
>A>	+	!	EQ 0.00125MG BASE/INH	N 021936	002	Sep 15, 2015	Mar	CHRS

TIVOZANIB HYDROCHLORIDE

>A>		CAPSULE; ORAL						
>A>		FOTIVDA						
>A>	+	AVEO PHARMS	EQ 0.89MG BASE	N 212904	001	Mar 10, 2021	Mar	NEWA
>A>	+	!	EQ 1.34MG BASE	N 212904	002	Mar 10, 2021	Mar	NEWA

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	CADILA	EQ 2MG BASE	A 208187	001	Mar 09, 2018	Feb	CAHN
AB		EQ 4MG BASE	A 208187	002	Mar 09, 2018	Feb	CAHN
	@ MYLAN	EQ 2MG BASE	A 076354	001	Mar 28, 2003	Jan	DISC
	@	EQ 4MG BASE	A 076354	002	Mar 28, 2003	Feb	DISC

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

>A>	AN	ALKEM LABS LTD	300MG/5ML	A 212848	001	Apr 01, 2021	Mar	NEWA
	AN	AUROBINDO PHARMA LTD	300MG/5ML	A 210871	001	Jan 22, 2021	Jan	NEWA

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	GLAND PHARMA LTD	0.3%	A 212628	001	Mar 09, 2021	Feb	NEWA
----	------------------	------	----------	-----	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	GLAND PHARMA LTD	EQ 10MG BASE/ML	A 209621	001	Feb 11, 2021	Feb	NEWA	
AP		EQ 40MG BASE/ML	A 209621	002	Feb 11, 2021	Feb	NEWA	
		TOBRAMYCIN SULFATE (PHARMACY BULK)						
AP	!	FRESENIUS KABI USA	EQ 40MG BASE/ML	A 065120	001	Nov 29, 2002	Jan	CTEC
AP		GLAND PHARMA LTD	EQ 40MG BASE/ML	A 209346	001	Feb 09, 2021	Jan	NEWA

TOFACITINIB CITRATE

SOLUTION; ORAL

XELJANZ

+	!	PFIZER	EQ 1MG/ML BASE	N 213082	001	Sep 25, 2020	Feb	CMS1
---	---	--------	----------------	----------	-----	--------------	-----	------

TOLCAPONETABLET; ORAL
TOLCAPONE

@	ALVOGEN	100MG	A207729	001	Jul 29, 2020	Jan	DISC
---	---------	-------	---------	-----	--------------	-----	------

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
TOLTERODINE TARTRATE

AB	AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	Jan	CMFD
AB		4MG	A213397	002	May 19, 2020	Jan	CMFD
AB	AMTA	2MG	A213858	001	Feb 02, 2021	Jan	NEWA
AB		4MG	A213858	002	Feb 02, 2021	Jan	NEWA

TOLVAPTANTABLET; ORAL
SAMSCA

	+ OTSUKA	15MG	N022275	001	May 19, 2009	Feb	CAHN
AB	+!	30MG	N022275	002	May 19, 2009	Feb	CAHN
	+ @	60MG	N022275	003	May 19, 2009	Feb	CAHN

TOPIRAMATECAPSULE, EXTENDED RELEASE; ORAL
TOPIRAMATE

AB2	GLENMARK PHARMS LTD	25MG	A210278	001	Feb 01, 2021	Jan	NFTG
AB2		50MG	A210278	002	Feb 01, 2021	Jan	NFTG
AB2		100MG	A210278	003	Feb 01, 2021	Jan	NFTG
AB2		150MG	A210278	004	Feb 01, 2021	Jan	NFTG
AB2		200MG	A210278	005	Feb 01, 2021	Jan	NFTG
AB1	ZYDUS PHARMS	25MG	A207382	001	Nov 24, 2017	Jan	CTEC
AB1		50MG	A207382	002	Nov 24, 2017	Jan	CTEC
AB1		100MG	A207382	003	Nov 24, 2017	Jan	CTEC
	TROKENDI XR						
AB1	+ SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Jan	CTEC
AB1	+!	50MG	N201635	002	Aug 16, 2013	Jan	CTEC
AB1	+!	100MG	N201635	003	Aug 16, 2013	Jan	CTEC

TRAMADOL HYDROCHLORIDETABLET; ORAL
TRAMADOL HYDROCHLORIDE

AB	POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Feb	CMFD
----	----------------	------	---------	-----	--------------	-----	------

TRANEXAMIC ACIDINJECTABLE; INJECTION
CYKLOKAPRON

>A>	AP	+! PFIZER	100MG/ML	N019281	001	Dec 30, 1986	Mar	CAHN
>D>	AP	+! PHARMACIA AND UPJOHN	100MG/ML	N019281	001	Dec 30, 1986	Mar	CAHN

TRANEXAMIC ACID

AP	PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019	Jan	CAHN
----	----------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

TRANEXAMIC ACID

>D>	AB	APOTEX INC	650MG	A202286	001	Jan 27, 2014	Mar	DISC
>A>		@	650MG	A202286	001	Jan 27, 2014	Mar	DISC

TRAVOPROSTSOLUTION/DROPS; OPHTHALMIC
TRAVOPROST

>A>	AT	MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Mar	NEWA
-----	----	------------	--------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDETABLET; ORAL
TRAZODONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Feb	CMFD
AB		100MG	A204852	002	Feb 05, 2020	Feb	CMFD
AB		150MG	A204852	003	Feb 05, 2020	Feb	CMFD
AB		300MG	A204852	004	Feb 05, 2020	Feb	CMFD
	@ RISING	50MG	A072484	001	Apr 30, 1990	Jan	CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP	ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Feb NEWA
AP		2.5MG/ML	A211574	002	Feb 11, 2021	Feb NEWA
AP		5MG/ML	A211574	003	Feb 11, 2021	Feb NEWA
AP		10MG/ML	A211574	004	Feb 11, 2021	Feb NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
TRIAMCINOLONE ACETONIDE

AT	SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	Jan CAHN
AT		0.1%	A040671	002	Jun 09, 2006	Jan CAHN

OINTMENT;TOPICAL
TRIAMCINOLONE ACETONIDE

AT	PERRIGO ISRAEL	0.05%	A212460	001	Feb 05, 2021	Jan NEWA
----	----------------	-------	---------	-----	--------------	----------

TRIAZOLAM

TABLET;ORAL
HALCION

AB	+ PFIZER	0.125MG	N017892	003	Apr 26, 1985	Feb CAHN
AB	+!	0.25MG	N017892	001	Nov 15, 1982	Feb CAHN
	@	0.5MG	N017892	002	Nov 15, 1982	Feb CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL
CLOVIQUE

>A>	AB	CHARTWELL RX	250MG	A209731	001	Oct 21, 2019	Mar CAHN
>D>	AB	KADMON PHARMS LLC	250MG	A209731	001	Oct 21, 2019	Mar CAHN
		TRIENTINE HYDROCHLORIDE					
>A>	AB	CHARTWELL RX	250MG	A209415	001	Sep 16, 2019	Mar CAHN
>D>	AB	KADMON PHARMS LLC	250MG	A209415	001	Sep 16, 2019	Mar CAHN

TRILACICLIB DIHYDROCHLORIDE

POWDER;INTRAVENOUS
COSELA

	+!	G1 THERAP	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Feb NEWA
--	----	-----------	--------------------	---------	-----	--------------	----------

UMBRALISIB TOSYLATE

TABLET;ORAL
UKONIQ

	+!	TG THERAPS	EQ 200MG BASE	N213176	001	Feb 05, 2021	Feb NEWA
--	----	------------	---------------	---------	-----	--------------	----------

URSODIOL

CAPSULE;ORAL
URSODIOL

AB	STRIDES PHARMA	300MG	A210344	001	Jan 22, 2021	Jan NEWA
----	----------------	-------	---------	-----	--------------	----------

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL
VALGANCICLOVIR HYDROCHLORIDE

AB	MYLAN	EQ 450MG BASE	A205151	001	Mar 03, 2021	Feb NEWA
----	-------	---------------	---------	-----	--------------	----------

VALPROIC ACID

SYRUP;ORAL
VALPROIC ACID

>D>	@	CHARTWELL RX	250MG/5ML	A075782	001	Dec 22, 2000	Mar CMFD
>A>	AA		250MG/5ML	A075782	001	Dec 22, 2000	Mar CMFD

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

	@	HIKMA	EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020	Feb DISC
	@		EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Feb DISC

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

@	MYLAN	EQ 25MG BASE	A077166	001	Jun 13, 2008	Jan	DISC
@		EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Jan	DISC
@		EQ 50MG BASE	A077166	003	Jun 13, 2008	Jan	DISC
@		EQ 75MG BASE	A077166	004	Jun 13, 2008	Jan	DISC
@		EQ 100MG BASE	A077166	005	Jun 13, 2008	Jan	DISC

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	DEXCEL PHARMA	EQ 75MG BASE	A213927	001	Jan 21, 2021	Jan	NEWA
----	---------------	--------------	---------	-----	--------------	-----	------

VERICIGUAT

TABLET; ORAL

VERQUVO

+	MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021	Jan	NEWA
+		5MG	N214377	002	Jan 19, 2021	Jan	NEWA
+	!	10MG	N214377	003	Jan 19, 2021	Jan	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

VIGABATRIN

AA	ANNORA PHARMA	500MG/PACKET	A213519	001	Jan 26, 2021	Jan	NEWA
----	---------------	--------------	---------	-----	--------------	-----	------

TABLET; ORAL

VIGABATRIN

AB	DR REDDYS	500MG	A211539	001	Jan 29, 2021	Jan	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VILAZODONE HYDROCHLORIDE

>A>	AB	INVAGEN PHARMS	10MG	A208200	001	Apr 07, 2021	Mar	NEWA
>A>	AB		40MG	A208200	002	Apr 07, 2021	Mar	NEWA

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

@	FRESENIUS KABI USA	EQ 10MG BASE/ML	A076849	001	Apr 18, 2005	Jan	DISC
---	--------------------	-----------------	---------	-----	--------------	-----	------

VOCLOSPORIN

CAPSULE; ORAL

LUPKYNIS

+	AURINIA	7.9MG	N213716	001	Jan 22, 2021	Jan	NEWA
---	---------	-------	---------	-----	--------------	-----	------

VORICONAZOLE

INJECTABLE; INTRAVENOUS

VORICONAZOLE

AP	ALMAJECT	200MG/VIAL	A206398	001	Mar 23, 2016	Feb	CAHN
----	----------	------------	---------	-----	--------------	-----	------

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

>A>	AB	+	CONCORDIA	25MG	N020789	003	Aug 22, 2003	Mar	CAHN
>A>		+	@	50MG	N020789	002	Aug 22, 2003	Mar	CAHN
>A>	AB	+	!	100MG	N020789	001	Mar 27, 2000	Mar	CAHN
>D>	AB	+	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Mar	CAHN
>D>		+	@	50MG	N020789	002	Aug 22, 2003	Mar	CAHN
>D>	AB	+	!	100MG	N020789	001	Mar 27, 2000	Mar	CAHN

ZONISAMIDE

AB	UNICHEM	25MG	A214492	001	Jan 26, 2021	Jan	NEWA
AB		50MG	A214492	002	Jan 26, 2021	Jan	NEWA
AB		100MG	A214492	003	Jan 26, 2021	Jan	NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

GRANULES

250MG; 250MG; 65MG

A214039 001 Feb 23, 2021 Feb NEWA

BUDESONIDE

SPRAY, METERED; NASAL

RHINOCORT ALLERGY

>D> +! ASTRAZENECA 0.032MG/SPRAY N020746 003 Mar 23, 2015 Mar CAHN

>A> +! J AND J CONSUMER INC 0.032MG/SPRAY N020746 003 Mar 23, 2015 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>D> @ APOTEX 10MG A207235 001 Aug 12, 2016 Mar CMFD

>A> 10MG A207235 001 Aug 12, 2016 Mar CMFD

@ 10MG A207235 001 Aug 12, 2016 Jan DISC

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

GUARDIAN DRUG 100MG/5ML A210149 001 Aug 17, 2018 Jan CMFD

STRIDES PHARMA 100MG/5ML A211666 001 Feb 22, 2021 Feb NEWA

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL ANTI-DANDRUFF

>D> +! KRAMER 1% N020310 001 Oct 10, 1997 Feb CTNA

LORATADINE

TABLET; ORAL

LORATADINE

UNIQUE PHARM 10MG A214684 001 Jan 07, 2021 Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

LORATADINE

>D> @ GLAXOSMITHKLINE 10MG A075822 001 Feb 10, 2003 Jan DISC

>A> TENSHI 5MG A212795 001 Sep 18, 2020 Mar DISC

>D> @ 5MG A212795 001 Sep 18, 2020 Mar DISC

>D> 10MG A213294 001 Oct 30, 2020 Mar DISC

>A> @ 10MG A213294 001 Oct 30, 2020 Mar DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

NICORETTE

>A> + GLAXOSMITHKLINE EQ 2MG BASE N022360 001 May 18, 2009 Mar CAHN

>A> +! EQ 4MG BASE N022360 002 May 18, 2009 Mar CAHN

>D> + GLAXOSMITHKLINE CONS EQ 2MG BASE N022360 001 May 18, 2009 Mar CAHN

>D> +! EQ 4MG BASE N022360 002 May 18, 2009 Mar CAHN

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

ALEMBIC PHARMS LTD EQ 0.1% BASE A209919 001 Dec 07, 2018 Feb CMKT

EQ 0.2% BASE A209420 001 Apr 29, 2019 Jan CMKT

APOTEX INC EQ 0.2% BASE A090918 001 Dec 05, 2017 Jan CMKT

BARR LABS INC EQ 0.2% BASE A090848 001 Jul 13, 2015 Feb CMKT

>A> @ CIPLA EQ 0.2% BASE A206087 001 Dec 05, 2017 Mar CMKT

FDC LTD EQ 0.1% BASE A209282 001 Sep 26, 2019 Feb CMKT

MYLAN EQ 0.1% BASE A204392 001 Mar 21, 2018 Feb CMKT

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ WOCKHARDT EQ 75MG BASE A076760 001 Feb 24, 2006 Jan DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 02 FEBRUARY 2021

NO MARCH 2021 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2021 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002 >A>	10918816	Dec 14, 2035	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025		U-219		
	8895615	Nov 23, 2025		U-3054		
	8895616	Nov 23, 2025		U-219		
	8895616	Nov 23, 2025		U-3054		
	8895617	Nov 23, 2025		U-219		
	8895617	Nov 23, 2025		U-3054		
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10894039	Oct 06, 2037		U-185		
	10894039	Oct 06, 2037		U-3		
	>A> 10952998	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	>A> 10925835	Jun 14, 2038		U-2410		
	>A> 10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	>A> 10925835	Jun 14, 2038		U-2410		
	>A> 10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	>A> 10925835	Jun 14, 2038		U-2410		
	>A> 10945960	Jun 14, 2038	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10888499	Feb 14, 2022	DP			
	>A> 10959943	Apr 19, 2036		U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10888499	Feb 14, 2022	DP			
	>A> 10959943	Apr 19, 2036		U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499	Feb 14, 2022	DP			
	>A> 10959943	Apr 19, 2036		U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499	Feb 14, 2022	DP			
	>A> 10959943	Apr 19, 2036		U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10888499	Feb 14, 2022	DP			
	>A> 10959943	Apr 19, 2036		U-2825		
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	10918723	Sep 10, 2033		U-2310		
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002					FC	Jun 08, 2021
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 213424 001					>A> CGT	Sep 21, 2021
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Nov 05, 2036		U-3044		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Nov 05, 2036	U-3044			
<u>AZACITIDINE - ONUREG</u>						
N 214120 001					ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120 002					ODE-320	Sep 01, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003				>A> I-811 >A> NCE		Oct 16, 2022 Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001				>A> NCE		Oct 24, 2023
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001 >A>	10941095	Dec 23, 2023	U-2747			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001 >A>	10941095	Dec 23, 2023	U-2746			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001					NCE >A> ODE-333	Dec 03, 2025 Dec 03, 2027
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002					NCE >A> ODE-333	Dec 03, 2025 Dec 03, 2027
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001				>A> M-82		Feb 24, 2024
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001 >A>	10940156	Mar 08, 2037	U-2552			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	RE48059	Dec 23, 2028	DS			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002					NPP	May 10, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	003				NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	004				NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	005				NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838	001				NPP	May 10, 2021
<u>BUPIVACAINE - POSIMIR</u>						
N 204803	001	8153149	Sep 15, 2025	DP	NP	Feb 01, 2024
		8153661	Sep 15, 2025	U-3074		
		8753665	Sep 15, 2025	DP U-3074		
		8846072	Sep 15, 2025	DP U-3074		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	001	>A> 10946010	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	002	10874661	Sep 18, 2032	DP		
		>A> 10946010	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	003	>A> 10946010	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	004	>A> 10946010	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	005	>A> 10946010	Sep 18, 2032	DP		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242	006	>A> 10946010	Sep 18, 2032	DP		
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023	001				M-128	Dec 18, 2023
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887	001	>A> 10927129	Apr 28, 2026	DS DP	NCE	Jan 21, 2026
		8410103	Apr 28, 2026	DS DP U-3061		
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888	001	>A> 10927129	Apr 28, 2026	DS DP	NCE	Jan 21, 2026
		6838464	Feb 26, 2021	DS DP		
		7125879	Apr 21, 2025	DS DP U-3059		
		8080551	Apr 11, 2023	DS DP		
		8410103	Apr 28, 2026	DS DP U-3060		
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888	002	>A> 10927129	Apr 28, 2026	DS DP	NCE	Jan 21, 2026
		6838464	Feb 26, 2021	DS DP		
		7125879	Apr 21, 2025	DS DP U-3059		
		8080551	Apr 11, 2023	DS DP		
		8410103	Apr 28, 2026	DS DP U-3060		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	001				>A> I-854	Jan 22, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	002				>A> I-854	Jan 22, 2024
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	003				>A> I-854	Jan 22, 2024
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690	001	10864181	Mar 15, 2033	U-3017		
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365	001	10918608	Oct 14, 2035	U-3071	>A> ODE-326	Jul 31, 2027
		10918608	Oct 14, 2035	U-3072	>A> ODE-332	Jul 31, 2027
		10918608	Oct 14, 2035	U-3073		
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026	001	>A> 10287586	Nov 12, 2030	DS DP	>A> NCE	Feb 25, 2026
		>A> 10533174	May 04, 2021	DP		
		>A> 10781450	Nov 12, 2030	U-3089		
		>A> 8524880	Apr 02, 2026	DS DP U-3087		
		>A> 8524880	Apr 02, 2026	DS DP U-3088		
		>A> 9228187	Nov 12, 2030	DS DP		
		>A> 9416361	May 04, 2021	DS		
		>A> 9447415	Jun 28, 2025	DS DP		
		>A> 9758783	Nov 12, 2030	U-3088		
		>A> 9758783	Nov 12, 2030	U-3089		
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829	001	>A> 10933053	Sep 09, 2034	U-3090		
		>A> 10933053	Sep 09, 2034	U-3091		
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144	001				>A> CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144	002				>A> CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144	003				>A> CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144	004				>A> CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144	005				>A> CGT	Sep 20, 2021
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352	001	6706276	Mar 06, 2022	DP		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589	001				>A> NPP	Aug 15, 2021
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455	001	10786518	Jul 19, 2038	U-2978		
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963	001	10894012	Feb 07, 2037	U-3014		
		>A> 10933060	Feb 07, 2037	U-3014		
<u>CRIZOTINIB - XALKORI</u>						
N 202570	001				I-852	Jan 14, 2024
					>A> ODE-328	Jan 14, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					I-852 >A> ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	>A> 10918694	Feb 28, 2037	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10905662	Aug 16, 2036	U-1399		>A> ODE* >A> ODE* >A> PED	Aug 14, 2022 Dec 22, 2024 Feb 14, 2023
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10905662	Aug 16, 2036	U-1399		>A> ODE* >A> ODE* >A> PED	Aug 14, 2022 Dec 22, 2024 Feb 14, 2023
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	>A> 10933089	Jan 15, 2039	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	9034822	Jan 20, 2031			U-1759	
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	9034822	Jan 20, 2031			U-1759	
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	7866474	Aug 31, 2027	DP		Y	
	7866474*PED	Mar 02, 2028				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031			U-1759	
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - DEFERIPRONE</u>						
A 208800 001					PC	Mar 27, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001 >A>	10959996	Mar 07, 2036	U-3055			
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002 >A>	10959996	Mar 07, 2036	U-3055			
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003 >A>	10959996	Mar 07, 2036	U-3055			
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 001					>A> CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 002					>A> CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 003					>A> CGT	Sep 26, 2021
<u>EDOXYBAN TOSYLATE - SAVAYSA</u>						
N 206316 001 >A>	7365205	Apr 18, 2027	DS			
<u>EDOXYBAN TOSYLATE - SAVAYSA</u>						
N 206316 002 >A>	7365205	Apr 18, 2027	DS			
<u>EDOXYBAN TOSYLATE - SAVAYSA</u>						
N 206316 003 >A>	7365205	Apr 18, 2027	DS			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10864274	Oct 02, 2034	U-2720			
	7214506	Feb 22, 2026	U-281			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	10881659	Mar 14, 2034	U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-2652		ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-3032			
	10239867	Apr 09, 2027	DS DP U-2653			
	10239867	Apr 09, 2027	DS DP U-3033			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 001					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 002					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 003					PC	Mar 09, 2021
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	10842938	Dec 21, 2037	DP U-2980			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 003	10842938	Dec 21, 2037	DP U-2980			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034			
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10912781	Oct 23, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10912781	Oct 23, 2028	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	RE47769	Feb 02, 2029	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	RE47769	Feb 02, 2029	DP			
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u>						
A 213950 001					CGT	Aug 25, 2021
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u>						
A 212706 001					CGT	Jul 17, 2021
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001					>A> M-240	Feb 15, 2022
					>A> PED	Aug 15, 2023
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001					>A> M-240	Feb 15, 2022
					>A> PED	Aug 15, 2023
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002					>A> M-240	Feb 15, 2022
					>A> PED	Aug 15, 2023
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	>A> 10376470	May 01, 2033	DP U-3095			
	>A> 9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	>A> 10376470	May 01, 2033	DP U-3095			
	>A> 9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	>A> 10376470	May 01, 2033	DP U-3095			
	>A> 9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	>A> 10376470	May 01, 2033	DP U-3095			
	>A> 9763885	May 01, 2033	DP U-3095			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	>A> 10947183	Sep 28, 2035	DS DP			
	>A> 10950331	Sep 28, 2035	U-3098			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS DP U-2709			
	10519252	Oct 20, 2023	DS DP U-2710			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS DP U-2711			
	10519252	Oct 20, 2023	DS DP U-2712			
	10519252	Oct 20, 2023	DS DP U-3048			
	10519252	Oct 20, 2023	DS DP U-3049			
	7754702	Feb 15, 2028			U-1432	
	7754702	Feb 15, 2028			U-2555	
	7754702	Feb 15, 2028			U-2556	
	7754702	Feb 15, 2028			U-2557	
	8895612	Jan 08, 2027			U-1620	
	8895612	Jan 08, 2027			U-3050	
	8895612	Jan 08, 2027			U-3051	
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	10519252	Oct 20, 2023	DS DP U-2709			
	10519252	Oct 20, 2023	DS DP U-2710			
	10519252	Oct 20, 2023	DS DP U-3048			
	10519252	Oct 20, 2023	DS DP U-3049			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028			U-2555	
	7754702	Feb 15, 2028			U-2556	
	7754702	Feb 15, 2028			U-2557	
	8895612	Jan 08, 2027			U-1620	
	8895612	Jan 08, 2027			U-3050	
	8895612	Jan 08, 2027			U-3051	
	9376505	Oct 20, 2023	DS DP			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10933147	Dec 30, 2035			U-2450	
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	>A> 10918816	Dec 14, 2035		DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	>A> 10918816	Dec 14, 2035		DP		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	>A> 10918816	Dec 14, 2035		DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	>A> 10918816	Dec 14, 2035		DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	>A> 10918816	Dec 14, 2035		DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	>A> 10918816	Dec 14, 2035		DP		
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	>A> 7504095	Jan 31, 2025	DP U-3092		>A> NCE	Feb 26, 2026
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212642 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212643 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GLUCAGON - BAQSIMI</u>						
N 210134 001	10894133	Jan 03, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	>A> 10940110	Feb 26, 2029	DP U-1773			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 001	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001					>A> ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001					>A> ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002					>A> ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003					>A> ODE-338	Dec 21, 2027
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033	U-2399		>A> ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033	U-2399		>A> ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	>A> 10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	>A> 10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	>A> 10799505	Aug 15, 2036	DS			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10882840	Jul 11, 2026	U-1524			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001					NPP	Dec 04, 2023
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	>A> 10940177	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001	>A> 10420749	Jul 27, 2036	DS DP U-2633		>A> I-847	Mar 03, 2024
	>A> 10420749	Jul 27, 2036	DS DP U-3096			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	>A> 10420749	Jul 27, 2036	DS DP U-2633		>A> I-847	Mar 03, 2024
	>A> 10420749	Jul 27, 2036	DS DP U-3096			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	>A> 10940108	May 03, 2033	U-2985			
	>A> 10945948	May 03, 2033	U-2985			
<u>MANNITOL - BRONCHITOL</u>						
N 202049 001					NP >A> ODE-327	Oct 30, 2023 Oct 30, 2027
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10881663	Mar 08, 2039	U-3038			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	>A> 10285946	Apr 25, 2032	DP		>A> NCE	Feb 26, 2026
	>A> 10322182	Apr 25, 2032	DP			
	>A> 10543274	Apr 25, 2032	U-3093			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	>A> 10869928	Apr 25, 2032	DP			
	>A> 6992207	Jun 25, 2022	DS DP U-3093			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	>A> 10940128	Jun 14, 2030	DP U-3086			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	>A> 8680136	Aug 29, 2031	DS DP			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10874655	May 30, 2038	U-2371			
	10874656	May 30, 2038	U-2371			
	10874657	May 30, 2038	U-2371			
	>A> 10925866	Apr 28, 2028	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	>A> 10946101	Oct 01, 2030	U-1631			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030				
	6346532	Mar 27, 2022	DS DP			
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030				
	6346532	Mar 27, 2022	DS DP			
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 001					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 002					CGT	Aug 10, 2021
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	>A> 10035788	Oct 15, 2028	U-2043			
	>A> 10035788	Oct 15, 2028	U-3047			
	>A> 10035788	Oct 15, 2028	U-3097			
	>A> 7982043	Oct 08, 2025	U-2043			
	>A> 7982043	Oct 08, 2025	U-3047			
	>A> 7982043	Oct 08, 2025	U-3097			
	>A> 8518446	Nov 20, 2030	DP U-2043			
	>A> 8518446	Nov 20, 2030	DP U-3047			
	>A> 8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			
	>A> 8790708	Nov 05, 2030	DP U-2043			
	>A> 8790708	Nov 05, 2030	DP U-3047			
	>A> 8790708	Nov 05, 2030	DP U-3097			
	>A> 9139558	Oct 15, 2028	U-2043			
	>A> 9139558	Oct 15, 2028	U-3047			
	>A> 9139558	Oct 15, 2028	U-3097			
	>A> 9211291	Mar 24, 2030	U-2043			
	>A> 9211291	Mar 24, 2030	U-3097			
	9265784	Aug 04, 2029	U-3047			
	>A> 9630946	Oct 15, 2028	U-2043			
	>A> 9630946	Oct 15, 2028	U-3047			
	>A> 9630946	Oct 15, 2028	U-3097			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10882840	Jul 11, 2026	U-1524			
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 001					ODE-319	Aug 06, 2027
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002					ODE-319	Aug 06, 2027
<u>NITAZOXANIDE - NITAZOXANIDE</u>						
A 213820 001					CGT	Jun 05, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10814092	Oct 17, 2025	U-3037			
	10926054	Aug 13, 2029	DP			
	7947227	Oct 17, 2026	U-3037			
	8057742	Jan 18, 2026	U-3037			
	8226916	Aug 18, 2025	U-3037			
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025	U-3037			
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025	U-3037			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Nov 16, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Nov 16, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001					NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002					NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003					NCE	Oct 30, 2025
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		>A> ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		>A> ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9566252	Nov 02, 2022	U-1370			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEO</u>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	10940138	Dec 16, 2039	U-2849			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	>A> 8309112	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
	>A> 8808737	Jun 21, 2027	U-3085			
	>A> 8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	>A> 8309112	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
	>A> 8808737	Jun 21, 2027	U-3085			
	>A> 8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	>A> 8309112	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
	>A> 8808737	Jun 21, 2027	U-3085			
	>A> 8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	>A> 8309112	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
	>A> 8808737	Jun 21, 2027	U-3085			
	>A> 8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	>A> 8309112	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
	>A> 8808737	Jun 21, 2027	U-3085			
	>A> 8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	>A> 8309112	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
	>A> 8808737	Jun 21, 2027	U-3085			
	>A> 8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	>A> 8309112	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
	>A> 8808737	Jun 21, 2027	U-3085			
	>A> 8871779	Nov 22, 2029	DS			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	>A> 6335447	Nov 09, 2023	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	RE47739	Mar 05, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	RE47739	Mar 05, 2027	DS DP			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027		U-2622		
	10391075	Feb 12, 2027		U-3069		
	8778997	May 07, 2027		U-1627		
	8778997	May 07, 2027		U-2622		
	8778997	May 07, 2027		U-3069		
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	>A> 10941142	Jul 24, 2038	DP			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	>A> 10953000	Mar 23, 2037		U-1974		
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					>A> ODE-331	Oct 13, 2027
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					>A> ODE-331	Oct 13, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					M-14 PED	Nov 20, 2023 May 20, 2024
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
	9029533	Dec 22, 2026		U-1283		
	9029533	Dec 22, 2026		U-1699		
	9029533	Dec 22, 2026		U-1700		
	9029533	Dec 22, 2026		U-1701		
	9029533	Dec 22, 2026		U-836		
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498	001				>A> NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498	002				>A> NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498	003				>A> NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498	004				>A> NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498	005				>A> NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498	006				>A> NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498	007				>A> NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498	008				>A> NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498	009				>A> NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498	010				>A> NCE	Mar 18, 2026
<u>RELUGOLIX - ORGOVYX</u>						
N 214621	001	10350170	Feb 25, 2036	DP	NCE	Dec 18, 2025
		10449191	Sep 29, 2037	U-3020		
		10786501	Sep 29, 2037	U-3020		
		7300935	Jan 28, 2024	DS		
		8058280	Jan 28, 2024	DS DP		
		8735401	Feb 04, 2024	U-3019		
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022	001	7125879	Apr 21, 2025	DS DP U-1153		
		7125879	Apr 21, 2025	DS DP U-1307		
		7125879	Apr 21, 2025	DS DP U-1740		
		7125879	Apr 21, 2025	DS DP U-3068		
<u>RISDIPLAM - EVRYSDI</u>						
N 213535	001				>A> ODE-334	Aug 07, 2027
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001	>A> 7049320	Aug 19, 2028	DS DP U-1741		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399	001	>A> 7049320	Aug 19, 2028	DS DP U-1741		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	001	>A> 9517226	Aug 22, 2033	U-3084	M-82	Feb 16, 2024
		>A> 9937143	Aug 22, 2033	U-3084		
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620	002	>A> 9517226	Aug 22, 2033	U-3084	M-82	Feb 16, 2024
		>A> 9937143	Aug 22, 2033	U-3084		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	>A> 9517226	Aug 22, 2033	U-3084		M-82	Feb 16, 2024
	>A> 9937143	Aug 22, 2033	U-3084			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	>A> 10933120	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	>A> 10933120	Mar 15, 2033	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	>A> 10933120	Mar 15, 2033	DP			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					>A> ODE-336	Nov 25, 2027
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10864181	Mar 15, 2033	U-1532			
<u>SOFOBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001	>A> 9918970	May 18, 2031	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10912754	Jun 01, 2038	U-3082			
	>A> 10940133	Mar 19, 2040	U-3099			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10912754	Jun 01, 2038	U-3082			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10925896	Nov 13, 2028	DP			
	10925897	Nov 13, 2028	DP			
	10933090	Nov 13, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10925896	Nov 13, 2028	DP			
	10925897	Nov 13, 2028	DP			
	10933090	Nov 13, 2028	DP			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10896751	Mar 16, 2030	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001					>A> ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002					>A> ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003					>A> ODE*	May 24, 2025
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10888558	Dec 02, 2035	U-2582			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	10864159	May 28, 2029	DP U-778			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610511	Oct 10, 2034	U-2615		I-850	Dec 01, 2023
	10610511	Oct 10, 2034	U-3007		>A> ODE-330	Dec 01, 2027
	>A> 10945988	Jan 25, 2033	U-2149			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001					NP	Dec 01, 2023
					>A> ODE-329	Dec 01, 2027
<u>TAVABOROLE - TAVABOROLE</u>						
A 211963 001					PC	Apr 17, 2021
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	>A> 9549938	Feb 16, 2026	U-1951		Y	
	>A> 9549938*PED	Aug 16, 2026				
	>A> 9566289	Feb 16, 2026	DP		Y	
	>A> 9566289*PED	Aug 16, 2026				
	>A> 9566290	Feb 16, 2026	U-1970		Y	
	>A> 9566290*PED	Aug 16, 2026				
	>A> 9572823	Feb 16, 2026	U-1970		Y	
	>A> 9572823*PED	Aug 16, 2026				
<u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u>						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028			U-3077	
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028			U-3078	
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028	U-3077			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-851	May 28, 2023
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002					I-851	May 28, 2023
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	>A> RE46284	Sep 22, 2029	U-1751			
	>A> RE46284	Sep 22, 2029	U-2503			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	>A> RE46284	Sep 22, 2029	U-1751			
	>A> RE46284	Sep 22, 2029	U-2503			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	>A> 6821987	Apr 26, 2022	DS DP U-3100			
	>A> 7166722	Nov 16, 2023	DS			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	>A> 6821987	Apr 26, 2022	DS DP U-3100			
	>A> 7166722	Nov 16, 2023	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	10905694	Apr 07, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	10905694	Apr 07, 2030	DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	10085992	Mar 14, 2034	U-3081		NCE	Feb 12, 2026
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031	DP			
	10927120	Oct 25, 2031	DP			
	8598186	Oct 25, 2031	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034	U-3079			
	9487530	Mar 14, 2034	U-3080			
	9957276	Oct 25, 2031	DS			
<u>UMBRALISIB TOSYLATE - UKONIO</u>						
N 213176 001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
	10072013	Jul 02, 2033	U-3064			
	10414773	May 26, 2035	DS DP U-3063			
	10414773	May 26, 2035	DS DP U-3064			
	10570142	Jul 02, 2033	DS DP U-3063			
	10570142	Jul 02, 2033	DS DP U-3064			
	>A> 10947244	May 26, 2035	U-3063			
	>A> 10947244	May 26, 2035	U-3064			
	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033	U-3063			
	9669033	Jul 02, 2033	U-3064			
	9969740	May 26, 2035	DS DP U-3063			
	9969740	May 26, 2035	DS DP U-3064			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	>A> 10940141	Aug 10, 2040	U-1995			
	>A> 10952997	Oct 10, 2037	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	>A> 10940141	Aug 10, 2040	U-1995			
	>A> 10952997	Oct 10, 2037	U-1995			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031		U-3062		
	9604948	Nov 26, 2032	DS DP	U-3062		
	9993476	May 19, 2031		U-3062		
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		ODE-280	Aug 12, 2027
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037		U-3056	NCE	Jan 22, 2026
	7332472	Oct 17, 2022	DS DP U-3056			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41ST Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm